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CANCER RISK IN NIGERIAN WOMEN 
 
Michael N. Okobia, PhD 
 
University of Pittsburgh, 2005 
 
 
 Breast cancer is major cause of morbidity and mortality globally and the incidence 
appears to be rising faster in population groups that hitherto experience lower incidence. This 
case control study recruiting 250 women with breast cancer and 250 age-matched controls from 
four University Teaching Hospitals in Nigeria was designed to evaluate the risk factors for breast 
cancer in Nigerian women. Family history of breast cancer was associated with a 15-fold 
increased risk of breast cancer [Odd ratio (OR) = 14.99, 95% Confidence interval (CI), 1.98, 
113.47]. Also, waist to hip ratio (OR = 2.10, 95% CI 1.44, 3.06), history of abortion (OR = 2.83, 
95% CI 1.12, 7.19), increasing age at first childbirth (OR = 1.39 95% CI 1.11, 1.73) and higher 
level of education (OR = 1.31, 95% CI 1.07, 1.61) conferred increased risk of breast cancer. 
Increasing parity (OR = 0.87, 95% CI 0.77, 0.99) and increasing duration of breastfeeding (OR = 
0.75, 95% CI 0.62, 0.91) conferred protection against breast cancer. In the final multivariate 
conditional logistic regression in all women, carrying at least one low-activity COMT (Met) 
allele was associated with a significant 43% reduced risk of breast cancer (OR = 0.57, 95% CI 
0.36-0.91). While harboring the CYP1A1 M1 polymorphic variant was associated with non-
significant reduced risk of breast cancer (OR = 0.79, 95% CI 0.48-1.29), the CYP1A1 M3 
polymorphism conferred a non-significant 24% reduced risk of breast cancer (OR = 0.76, 95% 
CI 0.47-1.22). Results of this study have important public health implications; it has provided 
evidence for a role for reproductive and other variables in susceptibility to breast cancer in 
 iv
indigenous African women, thus contributing to the global epidemiologic literature on risk 
factors for breast cancer in populations of African ancestry. It has also provided data suggesting 
protection for breast cancer for women harboring the low-activity COMT (Met) allele of the 
codon 158 polymorphism of the COMT gene. In addition, the findings of this study will serve a 
useful resource tool in future research and policy decisions aimed at breast cancer control and 
prevention in these populations. 
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1. INTRODUCTION 
 
Breast cancer is the most common form of cancer among women, and the leading cause 
of death related death among women globally (Parkin et al, 1999). The lifetime risk of 
developing breast cancer is reportedly 1 in 8 for women in North America, and 1 in 12 for 
Western Europe. The incidence of breast cancer in women has been rising since the 1940s and 
the rise is occurring more rapidly in population groups that hitherto enjoyed a low incidence of 
the disease (Parkin et al, 1999). For many years, breast cancer incidence and mortality rates have 
been highest in North America and Northern Europe, intermediate in Southern Europe and Latin 
America, and lowest in Asia and Africa (Parkin et al., 1997). The steep rise in incidence in most 
countries of Northern Europe and North America from the early 1980s has been ascribed to the 
introduction of mammographic screening for breast cancer (Kelsey et al. 1993). In recent years, 
steep increases in breast cancer incidence and mortality rates have been reported in many Asian 
and Central European countries. Thus the magnitudes of the differences in incidence rates 
between countries such as Japan and the United States are less than they were previously (Kelsey 
et al., 1993). Over time, the world breast cancer burden has increased steadily with an almost 
doubling of the annual number of estimated new cases over a 20-year span, the increase being 
seen both in the developed as well as the developing countries (Parkin et al., 1988); Parkin et al., 
1985; Parkin et al., 1999; Sasco AJ, 2001).  
International differences in breast cancer incidence rates has been hypothesized to be 
partially related to variation in such factors as body weight (De Waard et al 1977), some aspects 
of diet (Amstrong et al., 1975), hormone levels (Henderson et al., 1991), and reproductive 
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 characteristics especially age at menarche (Henderson et al., 1991), and possibly menstrual cycle 
length, parity, and lactation (Wang et al., 1992). Differences in hormone levels among women in 
various countries have also been thought to play a role (Bernstein et al., 1993). Studies of 
migrants to the United States suggest that environmental factors rather than genetic factors are 
mainly responsible for the variation in breast cancer incidence rates among countries. 
 
Incidence of Breast Cancer in US Populations 
There are racial/ethnic variations in the incidence and mortality rates of breast cancer among 
the various ethnic/racial groups in the United States. Breast cancer is the most common cancer 
among women in every major ethnic group in the United States. Estimates of age-adjusted 
incidence rates per 100,000 by race/ethnicity in California for the 1988-1989 were 110.6 for 
white women, 96.3 for black women, 59.2 for Hispanic women, and 52.8 for Asian American 
women (Hoegh et al., 1992). Incidence rates are higher in whites than blacks above the age of 
40-45 years, but below this age range, blacks are at slightly higher risk than whites (Hoegh et al., 
1992). Younger average age at first birth among blacks appears to be one of the factors 
accounting for this phenomenon. High parity may be associated with breast cancer that is 
diagnosed in women younger than 45-50 years of age, but it appears to be protective against 
breast cancer diagnosed at older ages (Kelsey et al., 1993); thus the high parity of blacks than 
whites could be partly responsible for these risk differentials. 
 
Incidence trends of breast cancer in the US 
Between 1973 and 1998, incidence rates of invasive breast cancer increased for women 
age 40 and over, although rates grew more than two-and-a-half times faster among women age 
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 50 and older than for women in their 40s (Howe et al., 2001). Incidence rates for invasive breast 
cancer did not increase for women under age 40 during this time. Incidence rates of ductal 
carcinoma-in-situ (DCIS) increased for women of all ages during this same time period, although 
rates grew fastest in women over age 50 (Ernster et al., 1996). The perceptions of increasing 
numbers of breast cancer cases in young women in the late 1980s and early 1990s are largely due 
to the growth and aging of the US population, as many “baby boomer” women reached ages 25-
40 at that time (Howe et al., 2001). Since 1985, breast cancer incidence rates among women 
under age 40 have actually declined significantly at an average 1.3% per year. It is important to 
note that in the past decade, incidence rates of breast cancer have remained relatively unchanged 
in women of all racial and ethnic groups. 
There has been an important reduction in breast cancer death rates in the US in recent 
years beginning in the late 1990s (Howe et al., 2001). This decline in breast cancer mortality has 
been attributed to both improvements in breast cancer treatments and the benefits of 
mammography screening (Ries et al., 2001). 
 
Incidence of Breast Cancer in African Populations 
Although there are no accurate data on the incidence rate of breast cancer in most of sub-
Saharan Africa, data emerging from the few cancer registries within the region gives estimates of 
the incidence of the disease within various countries in the region. Reports from the Ibadan 
cancer registry in Nigeria estimated the incidence of breast cancer in Nigeria in 1976 to be 15.3 
per 100,000 but this rose to 33.6 per 100,000 by 1993 (Ihekwaba FN, 1992). The age 
standardized incidence rate (world standard population) from the Abijan cancer registry in Ivory 
Coast is 21.4 per 100,000 (Echimane et al, 2000). Other incidence figures from sub-Saharan 
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 Africa are 20.4 per 100,000 for the Harare cancer registry in Zimbabwe (Chokunoga et al., 2000) 
and 16.4 per 100,000 from Kyadondo County in Uganda (Wabinga et al., 2000). Some other 
registries have reported lower incidence figures of 10.9 per 100,000 in Conarkry, Guinea 
(Koulibaly et al., 1997), 10.2 per 100,000 from Bamako Mali (Bayo et al., 1990) and 3.4 per 
100,000 from Gambia cancer registry (Bah et al., 1990). Although the above incidence figures 
are much lower than the incidence of 79.3 per 100,000 in African American women in the U.S. 
(SEER, 1988-1992), there is general consensus that there is gross under-reporting due to low 
awareness, poverty, sociocultural factors and the absence of breast cancer-screening programs in 
countries within sub-Saharan Africa. 
For the past two centuries, it has been suspected that sex hormones particularly estrogens 
may play some role in the etiology of breast cancer. It was, however, in the early 1970s that the 
role of these hormones in the causation of the disease was demonstrated by MacMahon et al. 
(1973). In 1983, Pike and colleagues (1983) observed that when the age-incidence curve was 
plotted on a log-log scale, the curve produced assumed a straight line until approximately age 50 
years, when a decrease in the curve is noted, indicating that the premenopausal period probably 
creates a fertile period for the pathophysiological processes culminating in the manifestation of 
the disease. Since then, a lot of studies have been conducted in an attempt to explain the role of 
female hormones in the etiology and biological behavior of breast cancer. Several reproductive 
risk factors have been implicated in the etiology of the disease, including age at menarche and 
menopause, menstrual irregularity, age at first full-term pregnancy, parity, breastfeeding, and age 
at last childbirth. Other related hormonal factors include use of hormonal contraceptives, 
hormone replacement therapy and environmental exposure to hormone-related substances 
(xenohormones).  
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  Although recent studies have provided evidence for familial clustering of breast cancer, 
high penetrance genes are thought to account for only 5-10% of all cases of the disease (Johnson 
et al., 1995), indicating that over 90% of cases of breast cancer may be accounted for by low-
penetrance genes acting in concert with various environmental factors.  
Cytochrome P4501A1 (CYP1A1) and cytochrome P4501B1 (CYP1B1) genes are 
involved in the hydroxylation of estradiol and estrone to catechol estrogen intermediates. 
Catechol estrogens particularly 4-hydroxyestadiol and 16-hydroxyestradiol have been shown to 
induce DNA damage via formation of estrogen catechol-DNA adducts as well as the generation 
of superoxide radicals that have been associated with single strand DNA breaks and other toxic 
effects on proteins and other cellular macromolecules (Han et al. 1994). On the other hand, the 2-
hydroxy catechol estrogens including 2-OH estradiol and 2-OH estrone are devoid of estrogenic 
activity. COMT is one of the several phase II enzymes involved in the conjugation and 
inactivation of catechol estrogens. These enzymes are widely distributed in the body particularly 
in target organs prone to estrogen-induced carcinogenesis including the breast. In addition, 
different functional polymorphisms influencing the activity of these enzymes have been 
described and evidence is accumulating that these polymorphisms may determine inter-
individual differences in exposure to estrogen-related carcinogenic metabolites. 
In the past few decade efforts have been made to relate the above actions of estrogens and 
its metabolites in animal models to human breast carcinogenesis. Although studies in African 
American women have highlighted most of the reproductive risk factors for breast cancer in 
blacks, there is little data in the literature on the role of these variables in breast cancer 
susceptibility in African populations south of the Sahara. In the past decade, studies in molecular 
epidemiology have been devoted to quantifying the contribution of low-penetrance genes to 
5 
 breast cancer risk in various populations. Most of these studies have been conducted in 
Caucasian populations, with few emerging reports in Asian populations. Very little literature 
exist on the role of these genetic polymorphisms on breast cancer risk in populations of African 
descent in the US, partly because of the low participation rate of African-American women in 
such studies. The few studies that have recruited African-American women often are of very 
small sample sizes. Overall, there has been a lot of inconsistency in the reported effects of these 
polymorphic variants on breast cancer risk in various populations partly because these 
polymorphisms have different allele frequencies in various populations. For example studies 
have shown that the G to A transition mutation in the COMT gene confer increased breast cancer 
risk in Asian populations (Yim et al., 2001, Huang et al., 1999) but not in most Caucasian 
populations (Millikan et al., 1998; Lavigne et al., 1997) studied to date despite the fact that the 
low-activity allele of the COMT gene has a much higher prevalence in Caucasian populations 
compared with Asian populations. In addition, some CYP1A1 polymorphic variants such as the 
CYP1A1 M1 is associated with increased risk of breast cancer in African-American women but 
not in Caucasians. 
Overall, the existing literature on risk factors for breast cancer is inadequate particularly 
in populations of African descent. The present study, recruiting 250 Nigerian women with 
histologically confirmed breast cancer and 250 aged-matched control subjects, and aimed at 
evaluating the epidemiological and genetic risk factors for breast cancer in Nigeria women was 
designed to test the following hypothesis: 
6 
 Hypothesis 1 
Women with breast cancer will have lifetime/reproductive experiences associated with 
higher estrogen exposure compared to those without the disease. We speculate that women with 
breast cancer will have earlier age at menarche, later age at menopause, later age at first full-term 
pregnancy, lower parity, and shorter overall duration of breastfeeding compared to women 
without the disease. In addition, we hypothesize that women with breast cancer will be more 
likely to have positive history of breast cancer in first- and second-degree relatives compared to 
the control subjects. 
Hypothesis 2  
 Women with breast cancer are more likely to harbor the low-activity COMT (Met) allele 
of catechol-O-methyltransferase (COMT), the gene encoding the phase II enzyme responsible for 
the detoxification of the carcinogenic catechol estrogens particularly 4-hydroxyestradiol to its 
biologically inactive intermediate, 4-methoxyestradiol for subsequent excretion. We speculate 
that this slower rate of detoxification might lead to the accumulation of genotoxic metabolites 
such as 4-hydroxyestradiol thereby exposing women with this variant allele to increased risk of 
breast cancer. 
Hypothesis 3   
We also hypothesized that women with breast cancer will experience lower rate of 2-
hydroxylation of estradiol compared to control women. This lower 2-hydroxylation rate is based 
on the speculation that these cancer-bearing women will harbor cytochrome P450 1A1 
(CYP1A1) polymorphisms that encode enzymes with decreased catalytic activity. This will 
result in lower lifetime exposure to 2-hydroxyestradiol (a non-carcinogenic metabolite), which is 
7 
 converted to 2-methoxyestradiol. 2-Methoxyestradiol has been shown to exert anti-angiogenic, 
anti-tubulin, and antiproliferative properties on tumor cells. 
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2.1. ABSTRACT 
 
This study was aimed at evaluating the risk factors for breast cancer in Nigerian women. 
A case-control design recruiting 250 women with breast cancer and 250 age-matched female 
controls was adopted for the study. Both cases and controls were drawn from four University 
Teaching Hospitals located in Midwestern and Southeastern Nigeria. Data on the clinical and 
epidemiological characteristics of the respondents were collected using interviewer-administered 
structured questionnaires followed by the anthropometric measurements. The mean ages of the 
cases and controls were 46.1 and 47.1 years, respectively. Fifty-seven percent of the cases were 
premenopausal while 43% were post- menopausal. Using conditional logistic regression, the 
effects of the various risk factors for breast cancer in the study population were assessed. 
Positive family history of breast cancer in first- and second-degree relatives was associated with 
a 15-fold increased risk of breast cancer [Odd ratio (OR) = 14.99, 95% Confidence interval (CI), 
1.98, 113.47]. Also, waist to hip ratio (OR = 2.10, 95% CI 1.44, 3.06), history of abortion (OR = 
2.83, 95% CI 1.12, 7.19), increasing age at first childbirth (OR = 1.39 95% CI 1.11, 1.73) and 
higher level of education (OR = 1.31, 95% CI 1.07, 1.61) conferred increased risk of breast 
cancer. Increasing parity (OR = 0.87, 95% CI 0.77, 0.99) and increasing duration of 
breastfeeding (OR = 0.75, 95% CI 0.62, 0.91) conferred protection against breast cancer. The 
findings from this study have shown that family history and reproductive characteristics are 
significant predictors of breast cancer risk in Nigerian women.  
 
Key words: breast cancer, risk factors, Nigeria women. 
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 2.2. INTRODUCTION 
 
Breast cancer is currently the most common malignancy in Nigerian women and the 
incidence seems to be on the increase1. It has overtaken carcinoma of the cervix and if the 
present trend is maintained, it will become, for Nigeria, and most other developing countries, the 
most important non-communicable disease of the new millennium.  
The actual cause of breast cancer is unknown but studies have implicated age, gender, 
heredity, reproductive factors, diet and anthropometric characteristics as possible etiological 
factors. Most of the available literature on the role of these risk factors in breast susceptibility is 
drawn from Caucasian populations. While these factors may be at play in Nigerian women, it is 
important to note that there is considerable variation in the geographical, racial and ethnic 
distribution of the disease attributed to environmental and genetic factors2. Anecdotal 
observations by clinicians in Nigeria suggest that the epidemiological characteristics of the 
disease in Nigerian women differ from that in Caucasian populations. For example, most women 
with breast cancer in Nigeria are multiparous and they practice prolonged lactation, factors, 
which are thought to be protective against the disease.  
While several investigators have reported the clinical and pathological characteristics of 
breast cancer in Nigerian women,3-6 little is known about risk factors of the disease in this 
population3,7,8. Yet it is the nature of the disease that each society, race and population must seek 
to define the characteristics of the disease among its people and evolve appropriate management 
strategy. This study is aimed at identifying risk factors for breast cancer in Nigerian women. 
Identification of these factors may enhance the ability to prevent the disease by permitting better-
focused health education and other preventive strategies. 
11 
  
2.3. METHODS 
2.3.1. Study population 
The study participants consisted of 250 breast cancer cases and 250 age- and sex-matched 
(within 5 years) controls recruited from four University Teaching Hospitals in Midwestern and 
Southeastern Nigeria including the University of Benin Teaching Hospital, Benin-City; 
University of Nigeria Teaching Hospital, Enugu; Nnamdi Azikiwe University Teaching Hospital, 
Nnewi; and University of Port Harcourt Teaching Hospital, Port Harcourt. The study protocol 
and consent forms were approved by the Institutional Review Boards of these four hospitals and 
the University of Pittsburgh. The cases consisted of prevalent and incident cases of breast cancer 
that were seen within these hospitals during the period of study. Breast cancer was defined as 
histologically confirmed malignant breast disease. Hospital-based, age-and sex-matched controls 
were recruited at the time of their outpatient clinic visits or in-patient wards at each of the 
hospitals where cases were recruited.  The age match was within 1 to 5 years. Eligible controls 
were women who were being treated for non-hormonal and non-cancerous lesions.   
 
2.3.2. Recruitment of study participants 
Physicians at the various study sites reviewed in-patient and outpatient medical records for 
information regarding past medical history and current medical complaint to identify potential study  
participants. Brief information about the study was provided to these potential study participants 
after which those willing to participate in the study were asked to contact the investigators for 
further information about the study. 
12 
  
2.3.3. Data collection 
 Data was collected during one 30-minute visit.  First, key details of the study in respect of 
objectives of the study, study protocol, risks and benefits, confidentiality and rights of 
participants were explained to all potential participants. Those willing to participate signed 
informed consent after which questionnaires were administered by the investigators. The 
interview was conducted in English; however when participants did not understand English, 
literate adult relatives, who as a rule accompany patients to the hospital, explained contents of 
the questionnaire and consent forms to the study participants. Each potential participant had an 
option to refuse participation in the study. An opportunity was also granted for participants to ask 
any questions. 
The questionnaire was designed to gather demographic data including age, religion, 
educational and marital status and occupational history. Information in respect of use of alcohol, 
cigarette smoking, history of breast and other cancers in first- and second-degree relatives and 
position among siblings were also obtained. Reproductive characteristics related to age at 
menarche, age at first childbirth, duration of breastfeeding of each child, use of hormonal and 
surgical contraceptives, history of abortion, age at menopause and use of hormone replacement 
therapy were also noted. For case participants, age at diagnosis of breast cancer and treatment 
received were also noted. In addition knowledge of study participants about breast cancer was 
also obtained. 
13 
  
2.3.4. Anthropometric measurements 
Height, weight, waist and hip measurements were taken while the subject was standing.  
The height was measured with a vertical tape attached to the wall; the weight was taken using a 
calibrated scale; the waist measurement was made at the umbilicus; and, the hips were measured 
at the widest part of the buttocks. 
 
2.3.5. Data analysis 
All questionnaires were reviewed for missing or incorrect data before the end of the 
interview section with each participant. All forms were reviewed for suspicious data, and returned to 
the participant’s file to be confirmed or corrected the following day, if necessary. The data analysis 
was done using the Statistical Analysis System (SAS) software (Version 8.0). Descriptive analysis 
was carried out to characterize the demographic variables of the study participants. For logistic 
regression analysis, the variables were classified as follows: family history of breast cancer in first- 
and second-degree relatives (yes/no), waist/hip ratio dichotomized based on the median value in 
controls, abortion (yes/no), age at first childbirth (< 20 years, 20-24 years, 25-29 years, and ≥ 30 
years), education (< 8 years, 8 through 11 years, 12 years or completed High School, 
Vocational/Technical Training, Some College, Completed College, and Postgraduate), parity (none, 
1, 2, 3, 4, and ≥ 5), and duration of breastfeeding (1-12 months, 13-24 months, 25-36 months, 37-48 
months, and ≥ 49 months). Other categorical variables that were entered into the logistic regression 
include cigarette smoking (yes/no), alcohol consumption (yes/no), regularity of menses (yes/no), use 
of hormone contraceptive pills (yes/no), age at menarche (≤ 12 years, 13, 14, 15, 16, 17, and ≥ 18 
years), and age at menopause (≤ 45 years, 45-50 years, 51-55 years, and ≥ 55 years). Body mass 
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 index (BMI), calculated as weight divided by the square of height (kg/m2) was dichotomized based 
upon the median value of BMI among the controls (24.65 kg/m2). 
Conditional logistic regression was used to assess the strength of the association between 
each of the hypothesized risk factors and breast cancer risk. Each matched case was paired with 
the corresponding control to enable differences between the cases and controls to be calculated. 
First each variable was assessed alone. The strength of significant variables were further assessed 
by building multivariate models. 
2.4. RESULTS 
2.4.1. Socio-demographic characteristics of the study population 
Age distribution 
There were 250 cases (all females) of histologically confirmed breast cancer and 250 aged- 
and sex-matched controls that were recruited for this study. The participation rate in this study was 
very high as less than 1% of the patients were excluded from the study. Reasons for exclusion 
included refusal to allow a blood draw and patient’s unwillingness to participate in the study. The 
age at diagnosis for the breast cancer cases ranged from 17 years to 95 years with a mean of 
46.1±12.6 years. The peak age of the cases were in the 45-49 year age range [43 patients (17.2%0], 
closely followed by the 40-44 year age range [41 patients (16.4%)]. Eighty patients (32.0%) were 
below the age of 40 years while 22 patients (8.8%) were aged 65 years and older as shown in Figure 
2-1. The mean age of the controls was 47.1 years. 
 
Educational status 
Fewer cases [57 (22.8%)] than controls [91 (36.4%)] had less than eight years of 
education while more cases [136 (54.4%)] than controls [113 (45.2%)] completed High School 
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 or post High School education. In a conditional logistic regression model controlling for age, 
higher level of education (completed High School or post High School education) conferred a 
significant 31% increased risk of breast cancer (OR = 1.31, 95% CI 1.07, 1.61) as shown in 
Table 2-1. 
 
Marital status 
Majority of the cases [195 (78.0%)] and controls [190 (76.0%)] were married or living as 
married. Fewer cases [24 (9.6%)] than controls [36 (14.4%)] were never married. There were 
more women who had divorced among the cases [10 (4.0%)] compared with the controls [2 
(0.8%)]. Two-third of the patients (67%) presented in hospital with advanced stages of breast 
cancer (Manchester Stages III and IV). 
 
Usual adult occupation 
The majority of the study participants were engaged in trading; 82 cases (32.8%) versus 
100 controls (40.0%). Most of the traders were engaged in petty trading involving sale of food 
items and domestic wares. Slightly more cases [81 (32.4%) than controls [74 (29.6%) were 
employed in the public service. The most common jobs in the public service included teaching, 
secretarial duties and nursing. Similar proportions of cases and controls were engaged in farming 
at a subsistence level usually involving cultivation of food crops. The other less common 
occupations included catering, fashion designing and hairdressing. 
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Family history of cancer 
 A much higher number of cases (19) than controls (6) reported positive family history of 
various types of cancer. More cases (15) than controls (1) reported family history of breast 
cancer. Six of the family breast cancers in the cases were in first-degree relatives, comprising 
four in sisters and two in mothers while seven were in second degree relatives consisting of four 
in aunts, one in a grandmother, one in a cousin and one in a niece. Two of the cases reported 
history of breast cancer in two relatives; one was that of breast cancer in her sister and 
grandmother while the second reported history of breast cancer in her sister and cousin. The only 
control with positive family history of breast cancer was reported in a sister. Other cancers 
reported in family members in the cases include one case each of carcinoma of the cervix, 
carcinoma of the prostate, and one patient that reported history of liver cancer in her father and 
brother. The other cancers reported by control participants include two cases of squamous cell 
carcinoma of the skin, one case of oral cancer and one case of carcinoma of the larynx. There 
was one case of an unspecified abdominal cancer in a relative of one of the controls. As shown in 
Table 2-1, family history of breast cancer was strongly associated with a 15-fold increased risk 
of breast cancer (OR = 14.99, 95% CI 1.98, 113.47) in a conditional logistic regression age.   
 
Use of alcohol 
Alcohol consumption was slightly more common among the cases [83 (33.2%)] 
compared with the controls [70 (28.0%)]. Most of them were occasional drinkers and the types 
of alcohol consumed include beer, palm-wine, and locally brewed gin. Alcohol consumption was 
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 associated with a non-significant 29% increased risk of breast cancer among the study population 
(OR = 1.29, 95% CI 0.87, 1.90) as shown in Table 2-2. 
 
Cigarette smoking 
 Cigarette smoking was not a common practice among study participants as only two of 
the cases and two of the controls reported having smoked cigarettes regularly for more than six 
months. Cigarette smoking was not associated with increased risk of breast cancer. 
 
2.4.2. Reproductive characteristics 
Age at menarche 
 The age at menarche in cases (range10-20 years and mean 14.75 years) did not differ 
significantly from that of controls (range 10-20 years, mean 14.5 years). As shown in Table 2-2, 
later age at menarche (>14 years) was associated with a non-significant 11% increased risk of 
breast cancer (OR = 1.11, 95% CI 0.98, 1.26). 
 
Age at first childbirth 
 There were 210 parous women among the cases and 209 parous women among the 
controls. The age at first childbirth ranged from 14-44 years (mean 23.18 years) for the cases and 
14-42 years (mean 21.87 years) for the control participants. Fewer cases [48 (22.8%)] had their 
first childbirth before the age of 20 years compared with controls [73 (34.93%)]. More cases [29 
(13.81%)] than control participants [13 (6.22%)] had their first childbirth after the age of 30 
years. Older age at first childbirth was associated with a significant 39% increased risk of breast 
cancer in a model controlling for age (OR = 1.39, 95% CI 1.11, 1.73). 
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Duration of breastfeeding 
 All parous women among the study participants breastfed their babies ranging from 2-
216 months (mean 65.49 months) among the cases and 2-312 months for the controls (mean 
80.96 months). More cases [93 (44.50%)] than controls [68 (32.69%)] breastfed for 48 months 
and below while fewer cases [116 (55.50%)] than control participants [140 (67.31%)] breastfed 
for over 48 months. Breastfeeding was associated with a significant 25% reduction in breast 
cancer risk (OR = 0.75, 95% CI 0.62, 0.91). 
 
Parity  
 The parity of the cases ranged from 0-11 with a mean parity of 4 while parity among the 
controls ranged from 0-13 with a mean of 5. More cases (97) than controls (69) had five children 
and below while fewer cases (113) than controls (140) had more than five children. Higher parity 
was associated with a significant 12% reduced risk of breast cancer (OR = 0.88, 95% CI 0.81, 
0.96). 
 
Age at menopause 
 About equal number of cases [107 (42.8%)] and controls [108 (43.2%)] were 
postmenopausal. Fewer cases (11) than controls (17) attained menopause before the age of 45 
years while more cases (48) than controls (38) became menopausal between the ages of 45 and 
49 years. Slightly fewer cases (41) than controls (47) attained menopause between the ages of 50 
and 54 years. About equal number of cases (7) and controls (6) attained menopause after the age 
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 of 55 years. Older age at menopause was associated with a 7% non-significant increased risk of 
breast cancer (OR = 1.07, 95% CI 0.71, 1.60). 
 
Regularity of menses 
 Information about menstrual regularity was available in 227 cases, of which 27 (11.89%) 
reported irregular menses. Among the controls 231 provided information about menstrual 
regularity and 31 of them (13.42%) had irregular menses. Irregular menses was associated a 19% 
non-significant reduced risk of breast cancer (OR = 0.81, 95% CI 0.45, 1.44). 
 
Use of hormonal contraceptives 
 Use of hormonal contraceptives was reported among 43 (17.2%) of the cases and 32 
(12.8%) control participants. Hormone contraceptive use conferred a 40% non-significant 
increased risk of breast cancer among study participants (OR = 1.40, 95% CI 0.84, 2.34). 
 
Birth order 
 Information about birth order was available in 222 cases and 233 controls. The birth 
order of the cases ranged from 1-9 while the range is from 1-11 for the controls. About equal 
number of cases (136) and controls (135) were in the 1-3 birth order category while slightly 
fewer cases (68) than controls (77) were in the 4-6 category. Birth order was not associated with 
increased of breast cancer in the study population. 
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2.4.3. Anthropometric measurements 
Body mass index (BMI) 
 One hundred and thirty-six cases (54.4%) and 125 controls (50.0%) had BMI below 
24.65. Slightly fewer cases [114 (45.6%)] than controls [125 (50.0%)] had BMI above 24.65 (the 
median BMI for controls). Body mass index was not associated with increased risk of breast 
cancer (OR = 0.83, 95% CI 0.58, 1.19). 
 
Waist/Hip ratio 
 Median waist to hip ratios for the cases and controls were 0.92 and 0.90 respectively. 
Fewer cases [89 (35.6%)] than controls [133 (53.2%)] had waist/hip ratio of 0.90 and below 
while more cases [161 (64.4%)] than controls [117 (46.8%)] had waist/hip ratio above 0.90. 
Higher waist/hip ratio was associated with a 2.0 fold increased risk of breast cancer in a logistic 
regression model (OR = 2.0, 95% CI 1.39, 2.87) as shown in Table 2-1. 
 
2.4.4. Controlling for additional risk factors 
Significant predictors of breast cancer identified in the univariate conditional logistic 
regression model including family history of breast cancer, waist/hip ratio, abortion, education, 
marital status, age at first childbirth, parity and duration of breastfeeding were entered into the 
model and various combinations of risk factors were found to be significant as shown in Table 2-
3. Overall, family history of breast cancer, waist/hip ratio, age at first childbirth, duration of 
breastfeeding, and education remain significant with three variables in the model while family 
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 history of breast cancer, waist/hip ratio, age at first childbirth and education were retained in the 
model controlling for four additional factors. 
 
2.4.5. Analysis of menopausal status 
Further stratified analysis on the basis of menopausal status revealed that educational status 
(OR 1.45; 95% CI 1.09, 1.95), use of hormone contraceptives (OR 2.67; 95% CI 1.04, 6.82), and 
late age at first childbirth (OR 1.72; 95% CI 1.16, 2.53), were associated with significantly 
increased risk of breast cancer risk in postmenopausal women but not in premenopausal women. 
Longer duration of breastfeeding conferred a 33% reduced risk of breast cancer also in 
postmenopausal women (OR 0.67; 95% CI 0.48, 0.92). In premenopausal women, higher waist 
to hip ratio was associated with a significant 4-fold increased risk of breast cancer. 
 
2.5. DISCUSSION 
 
This study was aimed at examining the role of reproductive and other epidemiological 
risk factors in susceptibility to breast cancer among women in Midwestern and Southeastern 
Nigeria. We were interested in this subject because of the paucity of data on risk factors for 
breast cancer in sub-Saharan Africa. Establishing the risk factors of the disease is the first major 
step in understanding the etiology of the disease and designing appropriate control and 
preventive measures. Much of what has been reported about risk factors for breast cancer has 
come from studies conducted in populations in the other parts of the world. It is known that 
environmental factors may play considerable role in breast cancer susceptibility and most of the 
populations studied live in different geographical areas. We were therefore interested in 
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 assessing the risk factors that may be at play in a black population in Midwestern and 
Southeastern Nigeria. This population provides a particularly interesting environment for this 
study because of the very high population density in Midwestern and Southeastern Nigeria9, with 
a very high participation rate of over 99%. This is in contrast to the findings of other 
investigators who have reported low recruitment rates particularly for blacks in the United 
States10. 
The age of the breast cancer patients in this study ranged from 17 to 90 years with a mean 
of 46.1±12.6 years. Fifty-seven percent of the cases were premenopausal while 43% were 
postmenopausal and majority of the patients presented in hospital with advanced stages of the 
disease. The disease pattern in this study reflects the general picture in most sub-Saharan African 
populations. The mean age of in the cases in this study is slightly higher than that reported by 
Anyanwu4 in Eastern Nigeria (44 years), slightly lower than reports from Ibadan in Western 
Nigeria (48 years)3 but much lower than figures among blacks patients in Durban, South Africa 
(54±10.9 years)11 and Chris Hani Baragwanath Hospital in Soweto (50 years)12. Thus, in sub-
Saharan African countries breast cancer occurs at a much earlier age than in the case of patients 
in most developed populations. Interestingly, African-American patients also tend to present at a 
younger age. In one study, 33% were under 50 years of age, compared with 25% in the case of 
white patients studied13. The proportion of postmenopausal women among the cases in this study 
is higher than the 20% previously reported from Ibadan in Nigeria3 but considerably less than 
two-thirds reported in Caucasians14,15. 
 Among the relevant etiological factors identified in this study, family history of breast 
cancer in first- and second-degree relatives conferred a 15-fold increased risk of breast cancer, 
controlling for age but this risk was attenuated to eight-fold when additional factors including 
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 waist/hip ratio, age at first childbirth and education were added to the model. About 30.4% of 
breast cancer cases in this study fell within the category of familial and hereditary breast cancer 
using the criteria of Lynch and associates.15 This is in keeping with reports in other populations 
with detailed characterization of pedigree suggesting that familial and hereditary breast cancer 
constitute about 32% of the total incidence of breast cancer.16  
Waist/hip ratio, a surrogate marker for central adiposity was associated with a 2-fold 
increased risk of breast cancer in this study and it remained significant in premenopausal women 
when participants were further stratified by menopausal status. Epidemiological studies of body 
fat distribution using waist/hip ratio have produced contradictory results; some being positively 
related breast cancer,6,17-21 others showing no association; 22,23 inconsistencies in these findings 
being related to differences in study design and sample size. Abdominal obesity is linked to 
hyperinsulinemia in both pre- and post-menopausal women and estrogen production is increased 
in the presence of abdominal obesity24,25. Increased estrogen bioactivity is thought to be related 
to increased estrogen production in fat deposits and also to decreased estrogen binding because 
of decreased levels of sex hormone binding globulin and increased triglyceride levels. Women 
with abdominal obesity also show an increase in unbound testosterone levels and may in addition 
show an increased production of testosterone and dihydrotestoterone.26 Insulin levels affect 
plasma lipid levels, and dyslipidemia is increased in the presence of abdominal obesity. The 
relative importance of abdominal obesity and hyperinsulinemia is uncertain in relation to a role 
in mammary carcinogenesis, but in a subset of women, the metabolic/endocrine concomitants of 
hyperinsulinemia associated with changes in the bioactivity of insulin-like growth factors (IGFs) 
in breast tissue, might act synergistically with increased estrogen bioactivity27. 
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 A history of abortion was associated with increased risk of breast cancer among women 
in this study and this is consistent with emerging consensus on the increased risk of breast cancer 
particularly in women who had induced abortion after the first trimester of pregnancy. Since Segi 
et al28 provided epidemiological evidence for an association between induced abortion and breast 
cancer risk in 1957, several reports have appeared in the literature that showed either no risk or 
an elevated risk for breast cancer following induced abortion. In 1980, Russo and Russo29 
provided experimental evidence of the mechanism responsible for the protective effect of early 
full term pregnancy, the abrogation of which is one way induced abortion increases breast cancer 
risk. After an extensive and detailed meta-analysis of the existing literature on the subject, Brind 
et al30 noted that a significant positive association exists between induced abortion and breast 
cancer risk, independent of the effect an induced abortion has in delaying first full term 
pregnancy. Moreover, the increased risk is seen in both prospective and retrospective studies 
from around the world, in populations with the widest imaginable differences in ethnicity, diet, 
socioeconomic and lifestyle factors and which differ in many aspects of design, and whose data 
extend over more than half a century in time30. This finding is consistent with the existing 
knowledge on human biology, oncology and reproductive endocrinology, and supported by a 
coherent body of laboratory data as well as epidemiological data on other risk factors involving 
estrogen excess, all of which together point to a plausible and likely mechanism by which the 
surging estradiol of the first trimester of pregnancy, if it is aborted, may significantly add to a 
women’s breast cancer risk. 
Our study has demonstrated the protective effect of early age at first childbirth, increasing 
duration of breastfeeding and parity on breast cancer risk. First full-term pregnancy before age of 
18 years reduces the risk of breast cancer and the risk is significantly higher in women with first 
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 full term pregnancy after the age of 35 years31. Most studies have also found that for first births 
over the entire childbearing period, the higher a woman’s age at first birth, the higher the risk32. 
While some studies have reported no protective effect for early age at first full term pregnancy 
others have found that age over 30 years at first child birth was associated with an increased risk 
of breast cancer relative to nulliparous women33.  
The effect of parity on breast cancer risk is not clearly understood. In most studies, high 
parity is found to be associated with low rates of breast cancer, but the extent to which this 
relationship can be explained by an inverse association between parity and age at first birth 
varies between studies34. Several studies have reported a protective effect of parity independent 
of the effect of age at first full term pregnancy. Kvale et al35 found a consistent and highly 
significant inverse association between high parity and breast cancer. The apparent protective 
effect of high parity was found in all subgroups of the patients according to demographic 
variables and could not be explained by other reproductive factors. There appears to be 
consistency in this finding across studies conducted in both high-risk, intermediate-risk and low-
risk areas. The protective effect of parity seems stronger in postmenopausal than in 
premenopuasal women, possibly on account of the confounding effect of time since last birth in 
younger women.  
The long-term protective effects of pregnancy are contrasted with the observation that the 
risk of carcinogenesis is actually increased in the short term after a pregnancy36. It is known that 
hormones induce carcinogenesis by inducing cell proliferation, which is an essential component 
of carcinogenesis. This hypothesis is consistent with the observation that increased cell 
proliferation results in a larger pool of cells that are susceptible to defective DNA repair. This in 
turn leads to mutations, which are subsequently propagated through increased mitotic activity 
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 present in proliferating cells, and can result in cancer formation. However, it has been shown that 
full term pregnancy induces differentiation of cells in the terminal duct lobular unit (TDLU) in 
the breast and this effect produces the long term effect of slowing the cell cycle in the epithelial 
cells of this location, which allows more time for DNA repair, which in turn will lead to 
decreased carcinogenesis37.   
A number of epidemiological studies have investigated the relationship between 
breastfeeding and breast cancer risk. Our finding of a 25% reduction in risk conferred by 
breastfeeding is consistent with reports in the literature. Overall, studies suggest a 20-30 percent 
reduction in risk among women who have ever breastfed38. More consistently, a longer duration 
of breastfeeding has been associated with breast cancer risk reductions as great as 40-60 
percent39. Recently, age at first lactation has been identified as the arbiter of risk, with an earlier 
age at initiation of lactation being associated with a stronger reduction in risk for premenopausal 
women and possibly for postmenopausal women40. However, because of the very strong 
correlation between age at first birth and age at first lactation, the independent effect of age at 
first lactation is difficult to isolate. It is notable that in countries with low risk of breast cancer, 
the protection conferred by lactation appears to be stronger and to be sustained throughout the 
postmenopausal period as well.  
Higher education conferred an increased risk of breast cancer in this study, in keeping 
with reports in the literature41. Although, we did not measure socioeconomic status, an 
established risk factor for breast cancer in most studies42,43, education is a strong surrogate for 
socioeconomic status. The quest for higher education delays age at marriage and age at first 
childbirth and it is associated with reduced parity and reduced duration of breastfeeding; these 
factors have been shown to reduce breast cancer risk. 
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 In conclusion, this study has examined the relationship between various factors and 
breast cancer risk in Nigerian women. It has demonstrated increased breast cancer risk associated 
with family history of breast cancer, abdominal adiposity, abortion and higher education and the 
reduced risk conferred by various reproductive variables; these findings are consistent with 
reports in the literature. However, studies with larger sample sizes are recommended for better 
characterization of the role of these risk factors in breast cancer risk in Nigerian women. This 
will provide an enabling framework for developing breast cancer risk assessment tools for the 
population with the aim of identifying high-risk individuals for primary and secondary 
prevention. 
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Figure 2-1: Age distribution of breast cancer patients 
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Table 2-1: Conditional logistic regression comparing cases and controls. Significant predictors of breast 
cancer risk [Numbers (N), Percentages (%)], [Means (S.D.)], age-adjusted odds ratio, 95% confidence 
interval for cases and controls 
 
Variable 
  
Cases 
 
Control 
 
 
Odds ratio 
 
95% CI 
 
Family history of 
breast cancer 
 
Yes 
 
15   (6.00)a
 
1    (4.00)a
 
14.99 
 
1.98,113.47 
 No 235 (94.00)a 249 (96.00)a 1.00  
 
Waist/hip ratio 
(>0.90) 
 
Yes 
 
161 (64.40)a
 
117 (46.80)a
 
2.00 
 
1.39,2.87 
 No 89 (35.60)a 133 (53.20)a 1.00  
 
Abortion 
 
Yes 
 
18   (7.20)a
 
7    (2.80)a
 
2.43 
 
1.01,5.85 
 No 232 (92.80)a 243 (97.20)a 1.00  
 
Age at first full-term 
pregnancy 
  
23.18 (5.36)b
 
21.87 (4.74)b
 
1.39 
 
1.11,1.73 
 
Education >= High 
School 
 
Yes 
 
136 (54.40)a
 
113 (45.20)a
 
1.31 
 
1.07,1.61 
 No 114 (54.60)a 137 (54.80)a 1.00  
      
 
Parity 
 
 
 
4.1 (2.9)b
 
4.7 (3.1)b
 
0.88 
 
0.81,0.96 
 
Duration of 
breastfeeding 
  
65.48 (47.32)b
 
80.96 (53.67)b
 
0.75 
 
0.62,0.91 
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Table 2-2: Conditional logistic regression comparing cases and controls. Non-significant predictors of breast 
cancer risk [Numbers (N), Percentages (%)], [Means (S.D.)], age-adjusted odds ratio, 95% confidence 
intervals 
 
Variable 
  
Cases  
 
Control  
 
Odds ratio 
 
 
95% CI 
 
 
Cigarette smoking 
 
Yes 
    
    2   (0.80)a
     
    2   (0.80)a
 
1.00 
 
0.14,7.01 
 No 248 (99.20)a 248 (99.20)a 1.00  
 
Alcohol consumption Yes   83 (33.20)a   70 (28.00)a 1.29 0.87,1.90 
 No 167 (66.80)a 180 (72.00)a 1.00  
 
Irregular menses Yes   27 (11.89)a   31 (13.42)a 0.81 0.45,1.44 
  200 (66.11)a 200 (86.58)a 1.00  
 
Use of hormonal 
contraceptives 
Yes   43 (17.27)a   32 (12.85)a 1.40 0.84,2.34 
 No 206 (82.73)a 217 (87.15)a 1.00  
 
Age at menarche    14.75 (1.73)b   14.50 (1.60)b 1.11 0.98,1.26 
 
Age at menopasuse    48.72 (3.27)b   48.48 (3.90)b 1.07 0.71,1.60 
 
Height  163.49 (6.81)b 162.98 (6.54)b 1.01 0.98,1.04 
 
Weight    65.78 (15.68)b   66.23 (13.72)b 0.99 0.98,1.01 
 
 
BMI >24.65 
 
Yes 
 
114 (54.60)a
 
125 (50.00)a
 
0.87 
 
0.67,1.12 
 No 136 (54.40)a 125 (50.00)a 1.00  
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Table 2-3: Multivariate conditional logistic regression comparing cases and controls.  
Significant predictors of risk 
 
Variable 
 
Odd ratio (OR) 
 
95% Confidence Interval (CI) 
Family history of breast cancer 8.97 (1.12, 71.66) 
Waist/Hip ratio 1.90 (1.24, 2.93) 
Age at first childbirth 1.45 (1.13, 1.86) 
 
 
Variable 
 
Odd ratio (OR) 
 
95% Confidence Interval (CI) 
Family history of breast cancer 9.44 (1.17, 76.03) 
Waist/Hip ratio 2.00 (1.30, 3.09) 
Duration of breastfeeding 0.77 (0.63, 0.95) 
 
 
Variable 
 
Odd ratio (OR) 
 
95% Confidence Interval (CI) 
Family history of breast cancer 11.66 (1.50, 90.48) 
Waist/Hip ratio 2.01 (1.38, 2.93) 
Education 1.31 (1.62, 1.64) 
 
 
Variable 
 
Odd ratio (OR) 
 
95% Confidence Interval (CI) 
Family history of breast cancer 8.07 (1.003, 64.95) 
Waist/Hip ratio 1.98 (1.27, 3.10) 
Age at first childbirth 1.31 (1.01, 1.71) 
Education 1.33 (1.05, 1.74 
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3.1. ABSTRACT 
 
Life-long estrogen exposure has been recognized as a predictor of breast cancer risk in 
women. Since polymorphisms in candidate genes involved in estrogen metabolism may 
contribute to determining life-time exposure to estrogen and its biologically diverse metabolites, 
we utilized a polymerase chain reaction (PCR)-based restriction fragment length polymorphism 
(RFLP) assay to assess the relationship between a G to A transition polymorphism in the 
catechol-O-methyltransferase (COMT) gene and breast cancer risk in a case-control study 
recruiting 250 Nigerian women with breast cancer and their age-matched controls. The 
frequencies of the COMT (Val/Val), COMT (Val/Met) and COMT (Met/Met) genotypes in the 
control subjects were 0.53, 0.40 and 0.07 respectively. In the final multivariate logistic 
regression model in all women, carrying at least one of low-activity allele of the COMT gene 
(COMT [Val/Met] + COMT [Met/Met]) was associated with a significant 33% reduced risk of 
breast cancer (0R = 0.57, 95% CI = 0.36-0.91). In premenopausal women, harboring at least one 
low- activity COMT (Met) allele conferred a non-significant 31% reduced risk of breast cancer 
(OR = 0.69, 95% CI 0.40-1.18) while there was a 14% reduced risk of postmenopausal breast 
cancer (OR = 0.86, 95% CI 0.46-1.61) for carrying at least one low-activity COMT (Met) allele. 
Our results suggest that harboring the COMT polymorphism appears to confer some protection 
against breast cancer risk in this population. To the best of our knowledge, this is the first study 
evaluating the association between this genotype and breast cancer risk in indigenous African 
populations. We therefore suggest more studies to further assess the contribution of this 
polymorphism to breast cancer susceptibility in sub-Saharan African populations. 
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3.2. INTRODUCTION 
 
The standard mechanistic paradigm of estrogen-mediated carcinogenesis via estrogen 
receptor α-induced cell proliferation1,2 has been expanded to encompass emerging research data 
supporting a complementary genotoxic pathway mediated by the generation and redox cycling of 
reactive oxygen species through the metabolic effects of estrogen metabolites such 4-, and 16α-
hydroxy catechols and the estrogen quinones that result from the oxidation of catechols3,4. This 
paradigm shift is necessitated by evidence of estrogen-induced carcinogenesis in several animal 
models including the Syrian hamster kidney cells5,6, the uterus of CD-1 mice7, mouse mammary 
gland8, and pituitary of rats9 following exposure to these estrogen metabolites. 
Although several enzymes have been implicated in the hepatic and extrahepatic  
hydroxylation of endogenous estrogens in animals and humans, attention has focused on the 2-, 
4-, and 16-hydroxylation pathways because of the known actions of metabolites in these 
pathways in both humans and animals. 4-Hydroxyestradiol has been shown to exhibit strong 
carcinogenic activity in several animal models including the male Syrian hamster kidney5,6 and 
rat pituitary9. 4-Hydroxyestradiol carcinogenicity has been attributed to its ability to bind the 
classical estrogen receptor10, undergo metabolic redox cycling11 to generate superoxide radicals 
and chemically-reactive quinone and semiquinone intermediates which damage DNA and other 
cellular macromolecules12, induce cell transformation and initiate tumorigenesis4. On the other 
hand, the 2-hydroxyl metabolites including 2-hydroxyestradiol and 2-hydroxyestrone lack 
carcinogenic activity and in fact, 2-methoxyestradiol (a product of subsequent O-methylation of 
2-hydroxyestradiol) is a very potent inhibitor of tumor cell proliferation13 and angiogenesis14.  
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 The recent finding that chronic administration of quercetin (a substrate and inhibitor of 
catechol-O-methyltransferase) to male Syrian hamsters significantly increased the severity of 
estradiol-induced kidney tumors15, and the correlation of this effect with inhibition of enzymatic 
O-methylation of catechol estrogens during quercetin administration16 suggest that factors that 
decreased the rate of O-methylation (mediated by catechol-O-methyltransferase [COMT]) of 
estrogen catechols might increase the rate of breast and other tumors in both animals and 
humans. In addition recent studies have shown that there are marked person-to-person variations 
in catechol-O-methyltransferase activity in red blood cells17 and liver samples18, and the 
distribution of catechol-O-methyltransferase activity in the American population appears to 
follow a polymorphic bimodal pattern19. All these led to the hypothesis that women harboring 
the low-activity allele of the COMT gene might have a higher risk of estrogen-associated breast 
cancer due to decreased formation of antitumorigenic 2-methoxyestradiol and retarded 
inactivation of catechol estrogen intermediates (particularly 4-hydroxyestradiol which is 
hormonally active and potentially genotoxic). 
Available data from association studies conducted in predominantly Caucasian20-23 and 
Oriental populations24,25 have shown inconsistencies with some demonstrating some increased 
risk with the low-activity allele while others show some protection against breast cancer risk in 
women carrying the low-activity alleles. There are few reports on the role of this genetic variant 
in populations of African descent mainly among African American women and most of these 
studies suffer from inadequate sample size with the risk of spurious associations. To the best of 
our knowledge, there are no reports on the role of this genetic variant on breast cancer risk in 
sub-Saharan African populations. This case-control study was designed to examine the 
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 association between the G to A transition mutation in codon 158 of the COMT gene and breast 
cancer risk in Nigerian women, a population of indigenous African women. 
 
3.3. MATERIALS AND METHODS 
3.3.1. Subjects 
All the subjects for the study were recruited from four University Teaching Hospitals located 
in Midwestern and Southeastern Nigeria, including University of Benin Teaching Hospital, 
Benin City; Nnamdi Azikiwe University Teaching Hospital, Nnewi; University of Nigeria 
Teaching Hospital, Enugu; and University of Port Harcourt Teaching Hospital, Port Harcourt. 
Study protocols were approved by the Ethics and Research Committees of the Nigerian hospitals 
and the Institutional Review Board (IRB) of the University of Pittsburgh. Recruitment was 
conducted between September 2002 and April 2004. Two hundred and fifty women with breast 
cancer and 250 age- and institution-matched controls were recruited during the period of study. 
Cases consisted of women with histologically confirmed breast cancer and were recruited during 
surgical out-patient clinic visits or in-patient hospitalizations for treatment of breast cancer 
during the period. Control subjects were women attending surgical outpatient clinics or 
hospitalized for non-malignant surgical diseases such as road traffic accident and other injuries, 
abdominal conditions such as intestinal obstructions, inflammatory disorders such as 
cholecystitis, choledocholithiasis and appendicitis and urological diseases such as urolithiasis 
and urinary tract infections. Patients being managed for malignant diseases or hormonal 
disorders were excluded from the study. About 0.5% of eligible patients refused sample donation 
and were also excluded from the study. 
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  Patient recruitment was carried out in the outpatient surgical clinics and surgical wards of 
the participating Nigerian hospitals. Written informed consent was obtained from study 
participants after detailed explanation of key points of the study including study objectives, risks 
and benefits, confidentiality and the rights of participants. Data was collected using interviewer-
administered questionnaires targeted at demographic history including age, sex, religion, 
occupation, exposure to chemical fertilizers and pesticides, and rearing of domestic animals. 
Obstetric and gynecological history including age at menarche, age at first full-term pregnancy, 
parity, breastfeeding, age at menopause (for postmenopausal subjects), history of use of 
hormonal contraceptives and hormone replacement therapy and surgical oophorectomy. 
Information about social habits such as cigarette smoking and alcohol consumption was also 
obtained. Anthropometric measurements including height, weight, waist and hip circumference 
were taken at the end of the interview. 
 
3.3.2. Sample donation and preparation 
Thirty milliliters of whole blood was collected in two 15 ml plain vacutainers and 10ml 
of whole blood was also collected in one 10 ml K3 EDTA vacutainer tube from each of the study 
participants. The blood was stored in ice packs and centrifuged within 10 h of collection. Serum 
and clots from the plain vacutainer tubes were separated; the serum was aliquoted into ten 2 ml 
tubes while the clot was transferred into two plain 20 ml tubes. Samples in the K3 EDTA 
vacutainer tubes were also centrifuged and buffy coat collected and stored in 3 ml tubes. All the 
samples were stored at –20 oC in the various study sites in Nigeria and later transferred to the 
Nigerian coordinating center in Polar Pack –20 C ice packs for frozen shipments where the 
samples were stored at –20 oC and later shipped to University of Pittsburgh in dry ice using 
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 FEDEX services. Samples were stored at –70 oC at the University of Pittsburgh until DNA 
extraction. 
DNA extraction from buffy coats (and clots for subjects with no buffy coats) was carried 
out using QIAamp DNA Mini Kits (for buffy coats) and QIAamp DNA Midi Kits (for blood 
clots) protocols26,27. The extracted DNA was stored at 4 oC until used for PCR and RFLP 
analysis. 
 
3.3.3. PCR and RFLP analysis 
Genomic DNAs from the cases and control subjects were analyzed for the presence of the 
G to A transition polymorphism in the COMT gene by a PCR-based Restriction Fragment 
Length Polymorphism (RFLP) assay. PCR amplification of a 323 bp fragment of the COMT 
gene, including part the part of the exon 4 that contains the polymorphism was carried out using 
forward primer: CCT GCT CTT TGG GAG AGG T and reverse primer: GTC TGA CAA CGG 
GTC AGG TA. A 50 µl PCR reaction mixture containing 2 µl of genomic DNA, 8 µl of 
deoxynucleotide triphosphates, 1 µl each of forward and reverse primers, 5 µl of 10X buffer, 1.5 
µl of MgCl and 0.2 µl of Taq polymerase was placed in a MJ Research DYAD thermocycler. 
After denaturing for 5 min at 95 oC, the DNA was amplified for 35 cycles at 95 oC for 30 s, 58 
oC for 30 s, and 72 oC for 30 s, followed by a 5 min extension at 72 oC. A positive control 
containing genomic DNA (University of Pittsburgh Molecular Epidemiology Laboratory control) 
and a negative control containing everything except DNA were included in the PCR experiment. 
Five µl of each PCR product, including the controls, were ran on a 1% agarose gel to ensure that 
the expected 323 bp product was generated.  
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  Restriction digest for the DNA fragment was carried out using Nla III restriction enzyme. 
Fifteen µl of the PCR product was digested for 16 h overnight at 37 C with 5 units of Nla III 
(New England Biolabs). The product of the restriction digest was mixed with 10 µl of orange 
loading dye and ran on a 3% agarose gel (with Ethidium bromide) electrophoresis in a 1X Tris-
Borate-EDTA buffer at 200V for 60 min. Although the presence of a G at position 1947 
(COMT-codon 158) generated a unique 185 bp and 138 bp fragments, the 138 bp fragment was 
divided into unique 96 bp and 42 bp fragments when position 1947 contains an A as shown in 
Figure 3-1. The gels were visualized by UV and the RFLP gel electrophoresis products were read 
by two independent persons who were unaware of the identities of samples as either cases or 
controls. 
 
3.3.4. Statistical Analysis 
Statistical analysis was carried out using the Statistical Analysis System (SAS) software 
(Version 8.0). Conditional logistic regression was used to assess the association between the 
COMT genotypes and breast cancer risk. First all women were considered together in the 
analysis irrespective of menopausal status. Because there is evidence suggesting an interaction 
between some putative risk factors for breast cancer such as menopausal status and obesity, 
stratified analysis in premenopausal and postmenopausal women were carried out. Risk factors 
that were identified as significant predictors of breast cancer risk were controlled for in the final 
conditional logistic regression model involving all women. Further analyses controlling for these 
risk factors in stratified analysis based on menopausal status could not be carried out as some of 
the cells contain zero subjects. 
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3.4. RESULTS 
3.4.1. Demographic characteristics 
Participants in this study consisted of 250 women with breast cancer and 250 age- and 
institution-matched controls drawn from four University Teaching Hospitals in Midwestern and 
Southeastern Nigeria. The mean age of the cases and controls were 46.1 years and 47.1 years 
respectively. The risk factors identified for breast cancer in this population include family history 
of breast cancer in first- and second-degree relatives (OR = 14.99, 95% CI 1.98-113.47), 
waist/hip ratio greater than the median in the controls (OR = 2.00, 95% CI 1.39-2.87), history of 
abortion (OR = 2.43, 95% CI 1.01-5.85), older age at first full term pregnancy (OR = 1.39, 95% 
CI 1.11-1.73) and higher level of education (High School and above) (OR = 1.31, 95% CI 1.07-
1.61) as shown in Table 3-1. High parity (OR = 0.88, 95% CI 0.81-0.96) and longer duration of 
breastfeeding (OR = 0.75, 95% CI 0.62-0.91) conferred protection against breast cancer in these 
women. 
Of the 250 breast cancer cases and 250 control subjects, PCR-based RFLP assays 
employing Nla III restriction enzyme were successful in 231 cases and 229 controls respectively. 
Figure 3-1 illustrates the results of the PCR-based RFLP assay for the COMT polymorphism on 
eight representative samples. It shows that the COMT (Val/Val), COMT (Val/Met), and COMT 
(Met/Met) are easily distinguishable using this technique. 
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3.4.2. Allele and genotype frequencies 
All women 
As shown in Table 3-2, the frequencies of the COMT (Val) and COMT (Met) alleles 
among cases were 0.76 and 0.24 respectively and 0.73 and 0.27 respectively for control subjects 
for the entire sample. The frequencies of the COMT (Val) allele in the cases was slightly higher 
compared to the controls while the frequency of the COMT (Met) allele among the control 
subjects was slightly higher than in the cases but these were not significantly different. 
 As shown in Table 3-2, the COMT genotype frequencies were also not significantly 
different from between the cases and control subjects. The frequencies of the COMT (Val/Val), 
COMT (Val/Met), and COMT (Met/Met) in the cases 0.58, 0.38, and 0.05 respectively while the 
frequencies of these genotypes in the control subjects were 0.53, 0.40, and 0.07 respectively. 
 
Premenopausal women 
The frequency of the COMT (Val) allele in the cases (0.77) was slightly higher than that 
in the controls (0.72). Similarly, the frequency of the COMT (Met) allele was slightly lower in 
the cases (0.23) compared to the control subjects (0.28). There were slight differences in the 
distribution of the COMT genotypes in premenopausal women. The COMT (Val/Val) genotype 
was slightly higher in the control participants (0.59) compared to the cases (0.52). Conversely, 
the COMT (Val/Met) and COMT (Met/Met) genotypes were slightly lower in the cases 
compared to the controls as shown in Table 3-2. 
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 Postmenopausal women 
The COMT (Val) allele was slightly higher in the cases (0.76) compared to the controls 
(0.74) while the COMT (Met) allele frequency was higher in the controls (0.27) compared to the 
cases (0.24). The distribution of the COMT (Val/Val), COMT (Val/Met), and COMT (Met/Met) 
genotypes were similar in the cases and controls. The frequencies of the COMT (Val/Val), 
COMT (Val/Met), and COMT (Met/Met) genotypes in the cases were 0.55, 0.41, and 0.04 
respectively while the frequencies of these genotypes in the controls were 0.54, 0.39, and 0.07, 
respectively. 
 
3.4.3. COMT genotypes and breast cancer risk 
The strength of the association between the COMT genotypes and breast cancer risk was 
assessed using conditional logistic regression. First all women were considered together followed 
by subgroup analysis based on menopausal status. 
 
All women 
Table 3-3 shows the results of the conditional logistic regression analysis. Slightly more 
cases [133 (57.88%)] than controls [121 (52.84%)] were homozygous for the high-activity 
COMT (Val/Val) genotype while fewer cases [87 (37.66%)] than controls [91 (39.74%)] carried 
the heterozygous intermediate-activity COMT (Val/Met) genotype. Carrying the heterozygous 
intermediate-activity COMT (Val/Met) genotype was associated with a reduced risk of breast 
cancer although this was not statistically significant (OR = 0.70, 95% CI 0.45-1.10). Also fewer 
cases [11 (4.76%)] than controls [17 (7.42%)] were homozygous for the low-activity COMT 
(Met/Met) genotype. When the intermediate-activity COMT (Val/Met) and low-activity COMT 
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 (Met/Met) genotypes were combined in the logistic regression model, carrying at least one low-
activity COMT (Met) allele was associated with a 26% reduced risk of breast cancer although 
this was not statistically significant (OR = 0.70, 95% CI 0.45-1.10).  
Because it is has been shown that some of the known risk factors for breast cancer such 
as obesity can modulate the effect of COMT genotypes on breast cancer risk, a model controlling 
for significant risk factors for breast cancer that were identified in the descriptive analysis was 
developed. In the final conditional logistic regression model, carrying at least one low-activity 
COMT (Met) allele was associated with a significant 43% reduced risk of breast cancer (OR = 
0.57, 95% CI 0.36-0.91) as shown in Table 3-3. 
 
Premenopausal women 
Of the 142 premenopausal breast cancer cases and 142 premenopausal controls, the PCR-
based RFLP assay was successful in 128 cases and 128 controls. More cases [75 (58.59%)] than 
controls [67 (52.34%)] were homozygous for the high-activity COMT (Val/Val) genotype. 
Slightly fewer cases [46 (35.94%)] than controls [51 (39.84%)] carried the heterozygous 
intermediate-activity COMT (Val/Met) genotype. Heterozygosity was associated with a 33% 
reduced risk of premenopausal breast cancer (OR = 0.67, 95% CI 0.37-1.21) although this was 
not statistically significant. Slightly fewer cases [7 (5.47%)] than controls [10 (7.81%)] were 
homozygous for the low-activity COMT (Met/Met) genotype. There was an 11% non-significant 
reduced risk of premenopausal breast cancer associated with this genotype (OR = 0.89, 95% CI 
0.46-1.73). A model combining the heterozygous intermediate-activity COMT (Val/Met) and the 
homozygous low-activity COMT (Met/Met) genotypes conferred a non-significant 21% reduced 
risk of premenopausal breast cancer (OR = 0.69, 95% CI 0.40-1.18). Adjustment for descriptive 
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 risk factors in the conditional logistic regression model could not be carried out in subgroup 
analysis, as some of the cells contained zero subjects, thereby creating instability in the 
multivariate model. 
 
Postmenopausal women 
Slightly more cases [57 (55.34%)] than control subjects [54 (54.00%)] were homozygous 
for the high-activity COMT (Val/Val) genotype. Also slightly fewer cases [42 (40.78%)] than 
controls [39 (39.00%)] carried the intermediate-activity COMT (Val/Met) genotype. There was a 
17% reduced risk of postmenopausal breast cancer associated with carrying this genotype but 
this did not attain statistical significance (OR = 0.83, 95% CI 0.42-1.65). Although fewer cases 
[4 (3.88%)] than controls [7 (7.00%) were homozygous for the low-activity COMT (Met/Met) 
genotype, this was not associated with risk of postmenopausal breast cancer (OR = 1.00, 95% CI 
0.45-2.23)]. Combining individuals carrying the intermediate-activity COMT (Val/Met) and low-
activity COMT (Met/Met) genotypes as a group in the logistic regression model conferred a non-
significant 14% reduced risk of postmenopausal breast cancer (OR = 0.86, 95% CI 0.46-1.61). 
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3.5. DISCUSSION 
 
This case-control study was designed to evaluate the association between the codon 158 
G to A transition polymorphism in the COMT gene and breast cancer risk in Nigerian women, a 
population of exclusively African women. The frequency of 7.4% for the COMT-LL (Met/Met) 
genotype in the Nigerian control subjects in this study is 3-4 times lower than the 22-28% 
reported in US Caucasians20,21,23,29 and half the 13% in African Americans23 but close to the 
9.8% found among Korean women24 and 2 times higher than the 3.2% reported in Taiwanese 
control subjects25. The frequency of the COMT-HH (Val/Val) genotype among our control 
subjects (52.8%) is higher than corresponding figures in US Caucasians (22-36%)20,21,23,29, 
African Americans (42%)23 but lower than the figures in Koreans (62%)24 but similar to the 
frequency of this genotype among the Taiwanese (53%)25.  
In the final logistic regression model controlling for family history of breast cancer, 
waist/hip ratio, age at first full-term pregnancy, and education, we found a significant reduced 
risk of breast cancer for carriers of at least one COMT-L (Met) allele (OR = 0.56, 95% CI 0.34-
0.92) and a non-significant 13% reduced risk for homozygous carriers. This reduced risk for 
carrying at least one low activity COMT (Met) allele of the COMT gene was also noted in 
subgroup analysis based on menopausal status (31% in premenopausal women and 14% in 
postmenopausal women) although these were not statistically significant. This is in agreement 
with reports of some investigators20-22 but in agreement with that of others21-25. In the Carolina 
Breast Cancer Study recruiting both Caucasians (389 cases and 379 controls) and African-
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 American women (265 cases and 263 controls), Millikan et al.20 were unable to demonstrate any 
significant association between COMT (Val/Met) polymorphism and breast cancer risk overall 
or in subgroup analysis. In particular, there was a non-significant 20% reduced risk of breast 
cancer in African American women harboring both the heterozygous COMT (Val/Met) genotype 
(adjusted RRs = 0.8, 95% CI 0.5-1.2) and homozygous COMT (Met/Met) genotype (adjusted 
RRs = 0.8, 95% CI 0.4-1.5) in a multivariate unconditional logistic regression model controlling 
for significant descriptive risk factors identified in their population. Risk for breast cancer was 
also not related to the COMT (Val/Met) polymorphism among Caucasian women in their study 
(adjusted RR = 0.8, 95% CI 0.6-1.1 for the COMT [Val/Met] genotype and adjusted RR = 0.7, 
95% CI 0.5-1.1 for the COMT [Met/Met] genotype). These authors also did not observe a 
positive association for COMT genotype among women who were physically inactive (recently 
or at age 12), who reported use of HRT or OC or who smoked cigarettes. In fact, their 
observation that women who were physically inactive showed a slightly inverse relationship with 
breast cancer risk was contrary to their hypothesis that women with low physical activity and 
low COMT activity will be at increased risk of breast cancer. 
Two studies among Caucasian populations have reported conflicting associations 
between the COMT codon 158 polymorphism and breast cancer risk particularly in subgroup 
analysis. Although Lavigne et al.21 (nested case control study recruiting 113 cases and 113 
controls) noted no significant overall relationship between the COMT (Val/Met) polymorphism 
and breast cancer risk (overall associations with heterozygosity  and homozygosity for the 
COMT (Met) allele were 1.30, 95% CI, 0.66-2.58 and 1.45, 95% CI, 0.69-2.58, respectively), 
they however reported that postmenopausal women homozygous for the COMT (Met) allele had 
a greater than two-fold increase in risk (OR = 2.18, 95% CI 0.93-5.11). Further stratified analysis 
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 in postmenopausal women based on body mass index (BMI) showed significant associations 
only among those whose BMI was greater than 24.47 kg/m2 (OR = 3.58, 95% CI 1.07-11.98). 
An inverse association between COMT (Val/Met) polymorphism was however noted in 
premenopausal women in their study (OR = 0.57, 95% CI 0.14-2.40 for the COMT [Val/Met] 
genotype and OR = 0.24, 95% CI 0.04-1.51 for the COMT [Met/Met) genotype.  
On the other hand, in a case control study of 281 case patients and 289 control subjects in 
western New York, Thompson et al.22 found that among premenopausal women with breast 
cancer, those with at least one low-activity allele showed significantly increased risk (OR=2.4; 
95% CI, 1.4-4.3) and the risk was stronger on further stratification based on BMI (OR=5.7; 95% 
CI, 1.1-30.1 for the heaviest premenopausal women. There was an inverse association between 
low-activity alleles and postmenopausal breast cancer, which was most pronounced among those 
who were COMT (Met/Met) (OR=0.40; 95% CI, 0.2-0.7); and this risk was strongest on further 
stratification based on body mass index (BMI) in the leanest women with at least one low-
activity allele (OR=0.3; 95% CI, 0.1-0.7). When COMT (Met/Val) individuals were combined 
with individuals who were COMT (Met/Met), having one or two low-activity alleles 
significantly decreased risk (OR=0.5; 95% CI, 0.3-0.9). Because the catechol estrogens are 
products of estrogen metabolism by CYP1A1 and CYP1A2, which are both induced by smoking, 
Ambrosone et al.23 have also presented data evaluating the role of COMT on breast cancer in 
smoking and nonsmoking women. It is interesting that increased risk was observed only among 
postmenopausal women who smoked and that inverse associations were significant only among 
postmenopausal nonsmokers.  
The results of the two studies among the Asian populations appear to demonstrate a more 
consistent association between the COMT polymorphism and breast cancer risk. Among Korean 
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 women, Yim et al.24 showed that in the total study population, subjects with at least one COMT-
L (Met) allele had an almost two-fold risk of breast cancer compared with the COMT-HH 
(Val/Val) genotype individuals (OR=1.7; 95% CI=1.04-2.78). Categorization by menopausal 
status revealed no difference in the distribution of COMT genotypes between the different 
menopausal groups. In a multigenic study on the combined impact of CYP17, CYP1A1, and 
COMT on breast cancer risk among Taiwanese women, Huang et al.25 compared the risk 
associated with harboring the high risk variants of these three genes in a case-control study 
recruiting 150 breast cancer cases and 150 hospital-based controls. The homozygous variants of 
the three polymorphisms evaluated (CYP17 A2/A2, CYP1A1 MspI vt/vt, and COMT L/L) were 
designated as the high-risk variants based on findings in their study. Individually, breast cancer 
risk associated with the susceptibility genotypes varied for the three genes and was much higher 
for COMT (P<0.05) than for CYP17 (P>0.05), and intermediate value for CYP1A1 (P<0.05). To 
determine whether the combined profiles of these estrogen-metabolizing genes may be 
associated with breast cancer, they examined breast cancer risk associated with combinations of 
these high-risk genotypes using women with the three putative low-risk genotypes as the 
reference groups. The authors found that the presence of at least one putative high-risk genotype 
was associated with increased risk of breast cancer. The risk of breast cancer increased 
significantly as the number of putative high-risk genotypes increased (p=0.006, based on Mantel 
extension test for a linear trend). Notably, none of the controls harbored all three high-risk 
genotypes. When genotype data was combined with other risk factors for breast cancer in the 
population for further analyses, it was discovered that harboring a high-risk COMT genotype is a 
stronger predictor of breast cancer risk than harboring a high-risk CYP17 or CYP1A1, 
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 suggesting that in Taiwanese women inactivation of catechol estrogens may be more important 
than their formation in breast cancer development. 
Overall, it is obvious that marked differences exist in the association of COMT genotypes 
and breast cancer risk even among studies in the same population. Some of these differences may 
be due to small sample size in some of the studies (Lavigne et al.20, 113 cases and 113 controls; 
Yim et al.24, 163 cases and 163 controls; and Huang et al.25, 150 cases and 150 controls). 
Although, our study sample size of 231 cases and 229 controls has 90% power to detect 
significant relationships between the COMT polymorphism and breast cancer risk in our study 
population, this was calculated based on the distribution of COMT genotypes in Caucasian 
populations. As already noted, the frequency of homozygous COMT (Val/Val), COMT 
(Val/Met), and COMT (Met/Met) genotypes in Caucasian controls (27%, 48%, and 25% 
respectively) differs significantly from the distribution of these genotypes in our control subjects 
(52.84%, 39.74%, and 7.42% respectively). Based on the above distribution, we speculate that a 
higher sample size will be required for detection of effects of COMT heterozygosity and 
homozygosity on breast cancer risk in our population compared to the Caucasian population. 
This is often one of the setbacks in early studies in populations with previously unknown 
genotype distriburions. In addition, differences in statistical analysis may also contribute to 
difficulties in comparing results of various studies. Although all the above-cited studies were 
matched on age, only Lavigne et al.20 performed conditional logistic regression. It is known that 
ORs may be overestimated when matched studies are analyzed with unconditional logistic 
regression. The effect of genotypes such as COMT on breast cancer risk may vary from one 
population to the other as a result of marked differences in the distribution of heterozygosity and 
homozygosity of the genotypes in the populations. The finding of interaction between COMT 
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 genotypes and menopausal status and obesity may also partly explain the differences in reports 
from various populations. In the developed countries with a much higher percentage of 
postmenopausal breast cancer and a higher proportion of obese women, COMT may be expected 
to have more impact on risk of the disease compared to the Nigerian population with a smaller 
percentage of postmenopausal women in a predominantly lean population. It should be noted that 
for a genotype such as COMT with a very high frequency of heterozygosity and homozygosity in 
various populations, a strong positive link to breast cancer risk would have created an 
evolutionary disadvantage for humans.  
About 70% of breast cancer patients in our study presented with advanced breast cancer 
(Manchester Stages III and IV). It is possible that we missed individuals with rapidly progressive 
breast cancer who may have died without reaching hospital. There is also no breast cancer-
screening program in Nigeria. Therefore patients with early preclinical disease may have been 
missed in our study. We do not know how this would have influenced out results. Progress in 
molecular cancer genetics is occurring at a very rapid rate. It is expected that new procedures 
utilizing rapidly advancing high through put techniques will soon replace studies based on single 
nucleotide polymorphisms (SNPs) in molecular cancer research. It is hoped that future molecular 
epidemiology cancer research in the next few decades will clarify our understanding of the 
contribution of low penetrance genes in the genesis of breast and other cancers. 
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Figure 3-1: COMT NlaIII Restriction Digest 
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Table 3-1: Conditional logistic regression comparing cases and controls. Significant predictors of breast 
cancer risk [Numbers (N), Percentages (%)], [Means (S.D.)], age-adjusted odds ratio, 95% confidence 
interval 
 
Variable 
  
Cases  
 
Control  
 
 
Odds ratio 
 
95% CI 
 
Family history of 
breast cancer 
 
Yes 
 
  15   (6.00)a
 
   1    (4.00)a
 
14.99 
 
1.98,113.47 
 No 235 (94.00)a 249 (96.00)a 1.00  
 
Waist/hip ratio 
(>0.90) 
 
Yes  
 
161 (64.40)a
 
117 (46.80)a
 
2.00 
 
1.39,2.87 
 No   89 (35.60)a 133 (53.20)a 1.00  
 
Abortion 
 
Yes 
 
  18   (7.20)a
 
   7    (2.80)a
 
2.43 
 
1.01,5.85 
 No 232 (92.80)a 243 (97.20)a 1.00  
 
Age at first full-term 
pregnancy 
  
  23.18 (5.36)b
 
  21.87 (4.74)b
 
1.39 
 
1.11,1.73 
 
Education >= High 
School 
 
Yes 
 
136 (54.40)a
 
113 (45.20)a
 
1.31 
 
1.07,1.61 
 No 114 (54.60)a 137 (54.80)a 1.00  
      
 
Parity 
 
 
 
    4.1 (2.9)b
 
    4.7 (3.1)b
 
0.88 
 
0.81,0.96 
 
Duration of  
breastfeeding 
  
  65.48 (47.32)b
 
  80.96 (53.67)b
 
0.75 
 
0.62,0.91 
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Table 3-2: COMT allele and genotype frequencies for breast cancer cases and controls 
  
Cases (n = 231) 
 
Controls (n = 229) 
 
 
All women 
 
  
Allele frequencies    
COMT-H (Val) 0.76 0.73 
COMT-L (Met) 0.24 0.27 
   
Genotype frequencies   
COMT-HH (Val/Val) 0.58 0.53 
COMT-HL (Val/Met) 0.38 0.40 
COMT-LL (Met/Met) 
 
0.05 
 
0.07 
Premenopausal women 
 
  
Allele frequencies   
COMT-H (Val) 0.77 0.72 
COMT-L (Met) 0.23 0.28 
   
Genotype frequencies   
COMT-HH (Val/Val) 0.59 0.52 
COMT-HL (Val/Met) 0.36 0.40 
COMT-LL (Met/Met) 
 
0.05 0.08 
Postmenopausal women 
 
  
Allele frequencies   
COMT-H (Val) 0.76 0.74 
COMT-L (Met) 0.24 0.27 
   
Genotype frequencies   
COMT-HH (Val/Val) 0.55 0.54 
COMT-HL (Val/Met) 0.41 0.39 
COMT-LL (Met/Met) 
 
0.04 0.07 
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Table 3-3: Distribution of polymorphisms of the COMT gene in relation to breast cancer 
  
Cases 
(unmatched) 
 
Controls 
(unmatched) 
 
OR (95% CI) 
(matched) 
 
OR (95% CI)a 
(matched)
 
 
All women 
    
COMT-HH (Val/Val) 133 (57.58) 121 (52.84) 1.00 1.00 
COMT-HL (Val/Met)   87 (37.66) 91 (39.74) 0.70 (0.45-1.10) 0.56 (0.34-0.92) 
COMT-LL (Met/Met)   11 (4.76) 17 (7.42) 1.00 (0.59-1.69) 0.87 (0.47-1.59) 
 
     
COMT-HH (Val/Val) 133 (57.58) 121 (52.84) 1.00 
 
 
COMT-HL+LL 
(Val/Met+Met/Met) 
98 (42.42) 108 (47.16) 0.74 (0.49-1.12) 0.57 (0.36-0.91) 
 
 
Pre-menopausal 
women 
    
COMT-HH (Val/Val) 75 (58.59) 67 (52.34) 1.00  
COMT-HL (Val/Met) 46 (35.94) 51 (39.84) 0.67 (0.37-1.21)  
COMT-LL (Met/Met) 7 (5.47) 10 (7.81) 0.89 (0.46-1.73) 
 
 
     
COMT-HH (Val/Val) 75 (58.59) 67 (52.34) 1.00 
 
 
COMT-HL+LL 
(Val/Met+Met/Met) 
53 (41.51) 61 (47.65) 0.69 (0.40-1.18)  
 
 
Postmenopausal 
women 
    
COMT-HH (Val/Val) 57 (55.34) 54 (54.00) 1.00  
COMT-HL (Val/Met) 42 (40.78) 39 (39.00) 0.83 (0.42-1.65)  
COMT-LL (Met/Met) 4 (3.88) 7 (7.00) 1.0 (0.45-2.23) 
2.0  
 
     
COMT-HH (Val/Val) 57 (55.34) 54 (54.00) 1.00 
 
 
COMT-HL+LL 
(Val/Met+Met/Met) 
46 (44.66) 46 (46.00) 0.86 (0.46-1.61)  
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4.1. ABSTRACT 
 
In this case-control study based on 250 women with breast cancer and 250 age-matched 
controls, we sought to evaluate the role of four polymorphic variants in the CYP1A1 gene in 
breast cancer susceptibility in Nigerian women. Heterozygosity for the CYP1A1 M1 genotype 
(CYP1A1 M1 [T/C]) was associated with a 21% reduced risk of breast cancer (OR = 0.79, 95% 
CI 0.46-1.40) while homozygosity for the genotype (CYP1A1 M1 [C/C]) conferred a non-
significant 9% reduced risk of breast cancer. These risk profiles were not significantly altered in 
subgroup analysis by menopausal status. While heterozygosity for the CYP1A1 M3 genotype 
(T/C) conferred a non-significant 24% reduced risk of breast cancer (OR = 0.76, 95% CI 0.47-
1.22), homozygosity for the variant was associated a non-significant 1.95-fold increased risk of 
breast cancer (OR = 1.95, 95% CI 0.24-6.01). Subgroup analysis showed a non-significant 11% 
reduced risk in premenopausal heterozygous carriers (OR = 0.89, 95% CI 0.45-1.44) and a non-
significant 6% increased risk of postmenopausal breast cancers for carriers of the CYP1A1 M3 
(T/C) genotype. The CYP1A1 M2 (isoleucine to valine) polymorphism in exon 7 and CYP1A1 
M4 (threonine to asparagine) variant in codon 461 of the CYP1A1 gene were found to be very 
rare in our study subjects. This study has shown that while the CYP1A1 M1 polymorphism 
conferred reduced risk of breast cancer, homozygosity for the CYP1A1 M3 (C/C) was associated 
with increased risk of breast cancer although these risks did not attain statistical significance. 
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4.2. INTRODUCTION 
 
Cytochrome P450 1A1 (CYP1A1) gene plays a central role in the 2-hydroxylation of 
estradiol and estrone (the two estrogens in humans) to 2-hydroxy catechol metabolites for 
subsequent O-methylation to 2-methoxy intermediates. While the 2-hydroxylation products (2-
OH estradiol catechol and 2-OH estrone catechol) are devoid of estrogenic activities1 and the 2-
methoxy derivatives shown to possess anti-proliferative and anti-angiogenic properties2-4, 
another mutually exclusive pathway of 16α-hydroxylation leads to metabolites with strong 
estrogenic properties and have been linked to estrogen-induced carcinogenesis in both laboratory 
animals and humans5-7.  
The CYP1A1 gene is highly polymorphic in human populations and ethnic differences in 
the distribution of these polymorphisms have been reported in various populations. Four 
polymorphisms including M1 (a threonine to cysteine substitution in the 3’ non-coding region)8, 
M2 (isoleucine to valine variant in codon 462 in the heme-binding domain in exon 7)9, M3 (an 
A-T to G-C transition mutation in the 3’ non-coding region 300 base pairs from the 
polyadenylation site)10, and M4 (a threonine to asparagine substitution in codon 461)11 have been 
described in various populations. It has been demonstrated by Crofts et al.12 that the exon 7 
polymorphism has a role in gene function by increasing both enzyme activity and mRNA levels 
in Asians. The same investigators found an increase in CYP1A1 mRNA in Caucasians who carry 
the double heterozygous genotype for the CYP1A1 M1 and CYP1A1 M2 (exon 7) 
polymorphisms, but no evidence for a functional significance of the exon 7 polymorphism alone. 
Association of CYP1A1 polymorphisms and breast cancer risk has been reported in various 
67 
 populations with inconsistencies even within populations. Taoli et al.13,14 observed an increased 
risk of breast cancer among a small sample of African American women (20 cases and 81 
controls) but not among Caucasian women who harbor the CYP1A1 M1 variant. Rebbeck et al.15 
found no association between the exon 7 polymorphism (M2) and breast cancer risk among US 
Caucasian women (96 cases and 146 controls) while Ambrosone and colleagues16 noted an 
increased risk of postmenopausal breast cancer among Caucasian women with the variant exon 7 
allele (216 cases and 282 controls). While Ishibe et al.17 reported that neither the CYP1A1 M1 
nor CYP1A1 M2 polymorphisms was independently associated with overall breast cancer risk, 
these investigators noted an interaction between these variants and smoking; current smoking 
and adolescent-onset smoking interacted with CYP1A1 M1 and CYP1A1 M2, respectively to 
increase breast cancer risk among Caucasian women in a case-control study nested in the Nurses’ 
Health Study. Studies in Asian populations have also reported conflicting results. While Huang 
et al.18 noted an increased risk among homozygous carriers of the CYP1A1 M1 polymorphism 
among postmenopausal Chinese women in Taiwan, Miyoshi and colleagues19 reported a 
significant 40% and 34% reduced risk of breast cancer for the CYP1A1 M1 and CYP1A1 M2 
variants in Japanese women.  
Apart from the small data from Taoli et al.13,14 noted above, we are unaware of any other 
association study of CYP1A1 genetic polymorphisms and breast cancer risk in women of 
African descent in the literature. Because of the wide ethnic differences in the distribution of 
CYP1A1 gene polymorphisms, this study recruiting 250 women with breast cancer and 250 age-
matched control subjects seeks to evaluate the association between CYP1A1 M1, M2, M3, and 
M4 polymorphisms and breast cancer risk in an exclusively African population drawn from 
Midwestern and Southeastern Nigeria. 
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4.3. MATERIALS AND METHODS 
 
4.3.1. Recruitment of study participants 
Two hundred and fifty cases of breast cancer and 250 age-matched women without the 
disease were recruited from four University Teaching Hospitals located in Midwestern and 
Southeastern Nigeria between September 2002 and April 2004 for this case-control study. Study 
protocols were approved by the Ethics and Research Committees of the Nigerian institutions and 
the Institutional Review Board (IRB) of the University of Pittsburgh. The cases were women 
with breast cancer being managed at the surgical out-patient clinics and surgical wards of the 
Nigerian hospitals. Control subjects were women without evidence of breast and other malignant 
diseases who were being treated for other surgical disorders including road traffic accidents, 
intestinal obstructions, chronic gallbladder diseases, appendicitis and non-malignant leg ulcers.  
 Eligible study participants were identified by with the assistance of physicians in these 
hospitals who informed them about the study and referred those willing to the study 
investigators. Details of the study including objectives, risks and benefits, confidentiality and 
right of participation were explained to eligible participants. Potential study participants were 
free to discuss participation with close family members. Written informed consent was obtained 
those that accepted to participate in the study.  
 Interviewer-administered questionnaires detailing sociodemographic characteristics 
including age, sex, occupation, exposure to chemical fertilizers and pesticides and obstetric and 
gynecological variables such as age at menarche, parity, age at first full-term pregnancy (FFTP), 
age at menopause, use of hormone contraceptives and hormone replacement therapy and history 
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 of abortions and surgical oophorectomy were used for data collection, which lasted 30 minutes. 
Height, weight, waist and hip circumferences were measured at the end of the interview. 
 
4.3.2. Biological samples 
Forty milliliters of whole blood collected in two 15 ml plain vacutainer tubes and one 10 ml 
K3-EDTA vacutainer tube was obtained from each study participant. Samples were centrifuged 
within 10 h of collection; buffy coat separated from plasma and red cells in the K3-EDTA 
vacutainer tubes were carefully pippeted into 3 ml tubes while clots separated from serum in the 
plain vacutainer tubes were turned into two 20 plain tubes and stored at –20 oC in each of the 
Nigerian study sites until transferred in polar ice packs to the Nigerian coordinating center at the 
University of Benin Teaching Hospital where samples were stored at –20 oC. The samples were 
later transferred to the University of Pittsburgh in dry ice and stored at –80 oC until DNA 
extraction. 
 
4.3.3. DNA extraction 
DNA extraction was from buffy coats and blood clots for participants in whom buffy coat 
was unavailable. QIAamp DNA Mini Kit20 and QIAamp DNA Midi Kit21 protocols were used 
for DNA extraction from buffy coats and blood clots respectively. The DNA was stored at 4 C 
until amplified by polymerase chain reaction (PCR) and used for restriction fragment length 
polymorphism (RFLP) analysis. 
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4.3.4. PCR and Genotyping 
Polymerase chain reaction (PCR) amplification and restriction endonuclease digest were 
carried out for each of the four CYP1A1 variants (CYP1A1 M1, M2, M3 and M4). Primers used 
for the PCR reaction, fragment lengths amplified and restriction enzymes used are detailed in 
Table 4-1. For the CYP1A1 M1 variant, a 348 base pair (bp) fragment containing part of exon 7 
and the adjoining 3’ non-coding region of intron 7 was amplified using the following primers 
(Forward [C1]: 5’ CCG CTG CAC TTA AGC AGT CT 3’, Reverse [C2]: 5’AGG GCG TAA 
GTC AGC ACA GT 3’. For the CYP1A1 M2 and CYP1A1 M4 polymorphisms, a 377 bp 
fragment containing part of exon 7 bearing the M2 and M4 variants was amplified using the 
following primers (Forward [C3]: 5’ GCA TTG ATC CTC CTG TCC AT, Reverse [C4]: 5’ 
AGG CAT GCT TCA TGG TTA GC 3’). A 400 bp fragment encompassing part of 3’ non-
coding region of the gene was amplified for the CYP1A1 M3 polymorphism using the following 
primers (Forward  [C5]: 5’ GGC CTC TGA GAA GCT CTG AA 3’, Reverse [C6]:  5’ GTC 
CTG GTG CCT GGA TAT GT 3’).  
 For each of the four polymorphisms, a 50 µl PCR reaction mixture containing 2 µl of 
genomic DNA, 8 µl of deoxynucleotide triphosphates, 1 µl each of forward and reverse primers, 
5 µl of 10X buffer, 1.5 µl of MgCl and 0.2 µl of Taq polymerase was placed in a MJ Research 
DYAD thermocycler. After denaturing for 5 min at 95 oC, the DNA was amplified for 35 cycles 
at 95 oC for 30 s, 58 oC for 30 s, and 72 oC for 30 s, followed by a 5 min extension at 72 oC. A 
positive control containing genomic DNA (University of Pittsburgh Molecular Epidemiology 
Laboratory control) and a negative control containing everything except DNA were included in 
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 the PCR experiment. Five µl of each PCR product, including the controls, were run on a 1% 
agarose gel to ensure that the expected fragments product was generated.  
 Restriction digest for each of the four variants of the CYP1A1 gene was carried out using 
restriction endonucleases detailed in Table I: CYP1A1 M1, MspI; CYP1A1 M2, BsrDI; 
CYP1A1 M3, MspI; and CYP1A1 M4, BsaI. Digestion for the CYP1A1 M1 MspI variant 
carried out at 37 oC overnight for 16 h revealed a band of 348 bp for the CYP1A1 M1 (T) allele 
and two bands of 230 bp and 118 bp for the CYP1A1 M1 (C) allele (Fig 4-1). BsrDI digest for 
the CYP1A1 M2 polymorphism, carried out for 16 h overnight at 65 oC, revealed a 377 bp 
fragment for the G allele and two bands of 237 bp and 140 bp for the A allele as shown in Figure 
4-2. For the CYP1A1 M3 variant, a 400 bp fragment for the T allele and two fragments of 330 
bp and 70 bp for the C allele were detected following a 16 h digestion at 37 oC and ran on 3% 
agarose gel electrophoresis stained with ethidium bromide as shown in Figure 4-3. Digestion for 
the CYP1A1 M4 variant with BsaI restriction endonuclease overnight for 16 h at 50 oC yielded a 
377 bp fragment for the A allele and two fragments of 277 bp and 150 bp for the C allele (Figure 
4-4). 
 
4.3.5. Statistical Analysis 
Data analysis was carried out using Statistical Analysis Systems (SAS) software (Version 
8.0). Assessment of association between socio-demographic characteristics and obstetric and 
gynecological variables and breast cancer risk was first carried out using conditional logistic 
regression. Because PCR amplification and RFLP analysis for the CYP1A1 M2 and M4 variants 
revealed that all individuals genotyped for CYP1A1 M2 variant carried the wild type CYP1A1 
M2 (A) allele except for one individual with the heterozygous CYP1A1 (A/G) genotype, and all 
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 the study subjects genotyped for the CYP1A1 M4 polymorphism were homozygous for the C 
allele (CYP1A1 M4 [C/C]), we restricted analysis of association between CYP1A1 genotypes 
and breast cancer risk to the CYP1A1 M1 and CYP1A1 M3 variants. Conditional logistic 
regression was used to evaluate association between these two CYP1A1 variants and breast 
cancer risk. First, all women were combined in univariate conditional logistic regression model 
restricted to each of the variants. Next variables that were found to be significant predictors of 
breast cancer risk in the descriptive analysis were entered into the multivariate conditional 
logistic regression models together with the genotype data. Subgroup analysis based on 
menopausal status was carried out separately for premenopausal and postmenopausal women. 
 
 
4.4. RESULTS 
 
4.4.1. Descriptive epidemiology 
Results of conditional logistic regression models evaluating the association of various 
socio-demographic and obstetric and gynecological variables are shown in Table 4-2. Family 
history of breast cancer (OR = 14.99, 95% CI 1.98-113.47), waist/hip ratio (OR = 2.00, 95% CI 
1.39-2.87), history of abortion (OR = 2.43, 95% CI 1.01-5.85), older age at first full-term 
pregnancy (OR = 1.39, 95% CI 1.11-5.85) and education above High School (OR = 1.31, 95% 
CI 1.07-1.61) were associated with increased risk of breast cancer. A 12% reduced risk of breast 
cancer was conferred by high parity (OR = 0.88, 95% CI 0.81-0.96); longer duration of 
breastfeeding was also associated with a significant 25% reduced risk of breast cancer (OR = 
0.75, 95% CI 0.62-0.91). 
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4.4.2. Association of CYP1A1 M1 polymorphism and breast cancer risk 
PCR-based RFLP assay for the CYP1A1 M1 polymorphism was successful in 220 cases 
and 218 control subjects out of 250 cases and 250 controls that were recruited for the study. The 
CYP1A1 M1 variant was found to be highly polymorphic in the study population as shown in 
Table 4-3. 
 
All women 
Allele frequencies for the CYP1A1 M1 (T) and CYP1A1 M1 (C) alleles were 0.77 and 
0.23 respectively among the cases and 0.76 and 0.24 respectively among the control subjects. 
Frequencies for the CYP1A1 M1 (T/T), CYP1A1 M1 (T/C) and CYP1A1 M1 (C/C) genotypes 
for the cases (0.61, 0.31, and 0.07 respectively) were not significantly different from the 
distribution of these genotypes in the control subjects (0.60, 0.33, and 0.08, respectively). When 
compared with the homozygous CYP1A1 M1 (T/T) genotype carriers, individuals harboring the 
heterozygous CYP1A1 M1 (T/C) genotype had a non-significant 21% reduced risk of breast 
cancer (OR = 0.79, 95% CI 0.46-1.40) in the final multivariate conditional logistic regression 
model controlling for other identified risk factors for breast cancer as shown in Table 4-4. 
Homozygosity for the CYP1A1 M1 (C/C) allele also conferred a non-significant 11% reduced 
risk of breast cancer in the final model (OR = 0.91, 95% CI 0.50-1.66). Combining heterozygous 
CYP1A1 M1 (T/C) and CYP1A1 M1 (C/C) carriers was associated with a non-significant 21% 
reduced risk of breast cancer. 
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Premenopausal women 
The distribution of the CYP1A1 M1 (T) allele and CYP1A1 M1 (C) allele in 
premenopausal breast cancer cases was not significantly different from the frequency of these 
alleles in the control subjects. While the allele frequencies in the cases were 0.78 and 0.22 
respectively for the T and C alleles, the frequencies of the T and C alleles in the control subjects 
were 0.75 and 0.25. Slightly more cases (78 [62.40%]) than controls (71 [57.26%]) were 
homozygous for CYP1A1 M1 (T/T) genotype while fewer cases (40 [32.00%]) than controls (43 
[34.68%]) carried the heterozygous CYP1A1 M1 (T/C) genotype. Seven cases (5.60%) and 10 
controls (8.06%) were homozygous for the CYP1A1 M1 (C) variant. There was a non-significant 
38% reduced risk of premenopausal breast cancer among carriers of the heterozygous CYP1A1 
M1 (T/C) genotype (OR = 0.62, 95% CI 0.31-1.24). Similarly, homozygosity for the CYP1A1 
M1 (C) allele conferred a non-significant 37% reduced risk of premenopausal breast cancer (OR 
= 0.63, 95% CI 0.28-1.44). Although, there was a 42% reduced risk of premenopausal breast 
cancer when the CYP1A1 M1 (T/C) and CYP1A1 M1 (C/C) genotypes were pooled together, 
this was also not statistically significant (OR = 0.58, 95% CI 0.31-1.09). 
 
Postmenopausal women 
Of the 108 cases of postmenopausal breast cancer patients and 108 age-matched controls, 
the PCR-based RFLP assay was successful in 103 cases and 104 control subjects. Slightly fewer 
cases (62 [60.19%]) than controls (58 [61.70%]) were homozygous for the CYP1A1 M1 (T) 
allele. Almost equal number of cases (31 [30.10%]) and controls (29 [30.85%]) harbored the 
heterozygous CYP1A1 M1 (T/C) genotype while slightly more cases (10 [9.71%]) than controls 
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 (7 [7.45%]) were homozygous for the CYP1A1 M1 (C) allele. Heterozygosity for the CYP1A1 
M1 variant (CYP1A1 M1 [T/C]) was not related to the risk of postmenopausal breast cancer (OR 
= 1.00, 95% CI 0.49-2.05) while homozygosity for the CYP1A1 M1 (C) allele (CYP1A1 M1 
(C/C) conferred a non-significant 16% increased risk of postmenopausal breast cancer (OR = 
1.16, 95% CI 0.55-2.44). Combining individuals heterozygous for the CYP1A1 M1 genotype 1 
[T/C]) and homozygous carriers of the variant (CYP1A1 M1 [C/C]) was associated with a non-
significant 6% increased risk of postmenopausal breast cancer (OR = 1.06, 95% CI 0.55-2.01). 
 
4.4.3. Association of CYP1A1 M3 polymorphism and breast cancer risk 
All women 
As shown in Table 4-5, the CYP1A1 M3 variant is highly polymorphic in the study 
population with allele frequencies of 0.88 and 0.12 for the CYP1A1 M3 (T) and CYP1A1 M3 
(C) alleles respectively among the cases and 0.87 and 0.13 for the CYP1A1 M3 (T) and CYP1A1 
M3 (C) alleles respectively among the control subjects. Slightly more cases (176 [76.86%]) than 
control subjects (172 [75.77%]) were homozygous for the CYP1A1 M3 (T) allele while almost 
equal number of cases (52 [22,71%]) and control subjects (53 [23.35%]) carried the 
heterozygous CYP1A1 M3 (T/C) genotype. Only one case (0.44%) and two controls (0.88%) 
harbored the homozygous CYP1A1 M3 (C/C) genotype. In the final multivariate conditional 
logistic regression model, heterozygosity for the CYP1A1 M3 genotype (CYP1A1 M3 [T/C]) 
conferred a non-significant 24% reduced risk of breast cancer (OR = 0.76, 95% CI 0.47-1.22) 
while homozygosity for the CYP1A1 M3 (C) allele (CYP1A1 M3 [C/C]) was associated with a 
non-significant 95% increased risk of breast cancer (OR = 1.95, 95% CI 0.24-6.01) as shown in 
Table 4-6. 
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Premenopausal women 
Of the 142 cases of premenopausal breast cancer and the 142 age-matched 
premenopausal controls, the PCR-based RFLP assay was successful in 126 cases and 126 
controls. The distribution of the CYP1A1 M3 (T) and CYP1A1 M3 (C) alleles in the cases (0.87 
and 0.13 respectively) is not significantly different from the distribution of these alleles in the 
control subjects (0.85 and 0.15, respectively). As shown in Table 4-5, slightly more cases (95 
[75.40]) than controls (90 [71.43%]) were homozygous for the CYP1A1 M3 (T) allele while 
fewer cases (30 [23.81%]) than controls (35 [27.78%]) carried the heterozygous CYP1A1 M3 
(T/C) genotype. While heterozygosity was associated a non-significant 19% reduced risk of 
premenopausal breast cancer (OR = 0.81, 95% CI 0.45-1.44), homozygosity for the CYP1A1 M1 
(C) allele was not related to premenopausal breast cancer risk (OR = 1.00, 95% CI .025-4.00). 
Combining heterozygous and homozygous carriers of the CYP1A1 M3 (C) allele did not alter 
the premenopausal breast cancer risk as shown in Table 4-6 (OR = 0.82, 95% CI 0.46-1.43). 
 
Postmenopausal women 
The PCR-based RFLP assay was successful in 103 out of 108 postmenopausal breast 
cancer cases and 99 out of 108 postmenopausal control subjects. CYP1A1 M3 (T) allele and 
CYP1A1 M3 (C) allele frequencies were similar in cases (0.89 and 0.11, respectively) and 
control subjects (0.90 and 0.10, respectively) as shown in Table 4-5. Slightly fewer cases (81 
[78.64%]) than controls (80 [80.81%]) were homozygous for the CYP1A1 M3 (T) allele while 
slightly more cases (22 [21.36%]) than controls (18 [18.18%]) carried the heterozygous CYP1A1 
M3 (T/C) genotype as shown in Table 4-6. Compared with the homozygous CYP1A1 M3 (T/T) 
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 carriers, heterozygosity (CYP1A1 M3 (T/C) was associated with a non-significant 6% increased 
risk of postmenopausal breast cancer (OR = 1.06, 95% CI 0.54-1.20). Risk associated with the 
homozygous CYP1A1 M3 (C/C) genotype could not be assessed as none of the postmenopausal 
breast cancer cases carried the homozygous CYP1A1 M3 (C/C) genotype. 
 
4.5. DISCUSSION 
 
CYP1A1 may be involved in breast cancer via estrogen-related mechanisms. Estrogens 
are metabolized by two competing pathways to form either inactive 2-hydroxy-estradiol and 
estrone or active 16α-hydroxy- estradiol and estrone, respectively; level of the latter are often 
elevated in breast cancer, and may be related to tumorigenesis22. CYP1A1 polymorphism may 
affect the distribution of these metabolites and thus determine susceptibility to cancer23,24. To 
date, four polymorphisms have been described within this gene; M1, M2, M3, and M4. It has 
been suggested that there is wide ethnic variation in the distribution of polymorphisms of the 
CYP1A1 gene. For example, the CYP1A1 M2 (Exon 7) polymorphism was found to be rare in 
our study population with only one heterozygous (CYP1A1 M2 [A/G]) carrier in the entire 
sample. This same polymorphism has been reported to have allele frequencies of 0.69 and 0.31 
among the Japanese8, and 0.88 and 0.12 among a racially mixed African American population25. 
Studies in Asian populations indicate that more than 10% of the population possesses variant 
genotypes of this polymorphism18. Allele frequencies of this polymorphism in Caucasians have 
been reported to be low (0.97 and 0.03)15. Also we did not find any carriers of the CYP1A1 M4 
(A) allele in our study subjects; all were homozygous for the CYP1A1 M4 (C) allele. On the 
other hand, the CYP1A1 M1 and CYP1A1 M3 variants were highly polymorphic among the 
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 Nigeria study subjects. Allele frequencies for the CYP 1A1 M1 (T) and CYP1A1 (C) alleles 
among our control subjects were 0.76 and 0.24 respectively with genotype frequencies of 0.60, 
0.33, and 0.08 for the CYP1A1 M1 (T/T), CYP1A1 M1 (T/C), and CYP1A1 M1 (C/C) 
genotypes respectively. The homozygous CYP1A1 M1 (C) frequency of 8% in this study agrees  
with the findings of Cosma et al.26 These investigators reported the frequency of the CYP1A1 
M1 (C/C) to be 6-7% in a small sample of African American women (21 cases and 85 controls). 
Our finding is however lower than the 13% reported for the homozygous CYP1A1 M1 (C/C) 
genotype among Asians but higher than the 2% reported in Caucasian populations26.  
The CYP1A1 M3 polymorphism has been reported previously only in African American 
women. We have found this variant to also be polymorphic in Nigerian women occurring with 
allele frequencies of 0.87 and 0.13 for the CYP1A1 M3 (T) and CYP1A1 M3 (C) alleles and 
among the control subjects. Among a small sample of African American women, Crofts et al.27 
observed a 17% carrier rate for the CYP1A1 M3 variant with CYP1A1 M3 (T) and CYP1A1 M3 
(C) allele frequencies of 0.91 and 0.09 respectively. 
Breast cancer risk association studies with CYP1A1 variants in the literature have been 
conflicting. We did not observe any significant association between the two common CYP1A1 
polymorphisms in our study population (CYP1A1 M1 and CYP1A1 M3) and breast cancer risk 
overall, or in subgroup analysis based on menopausal status. In particular, the CYP1A1 M1 
polymorphism was associated with a non-significant 19% reduced risk of breast cancer (OR = 
0.79, 95% CI 0.46-1.40). This same polymorphism was reported to confer almost 10-fold 
increased risk of breast cancer among African American women by Taioli et al.14 (OR = 9.7, 
95% CI 2.0-47.9) although their study was of small sample size (21 cases and 85 controls). 
These investigators were unable to demonstrate any association of CYP1A1 M1 polymorphism 
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 and breast cancer risk in Caucasian women in their study (OR = 1.7, 95% CI 0.6-4.9 for 
heterozygous carriers of the CYP1A1 M1 [T/C] genotype). 
Rebbeck et al.15 observed no association of breast cancer risk with the exon 7 
polymorphism among 96 incident breast cancer cases and 146 controls, whereas Ambrosone and 
colleagues16 reported a significant increase in risk among postmenopausal women with the 
variant exon 7 allele (based on 216 cases and 282 controls). In addition, an interaction was 
observed in the latter study with smoking, suggesting that this polymorphism may be important 
in increasing breast cancer risk among light smokers (defined as <30 pack-years). In a 
prospective study of 466 cases (over 99% Caucasians) and an equal number of controls nested in 
the Nurses’ Health Study, Ishibe et al.17 were unable to detect an overall increase in breast cancer 
risk with the variant CYP1A1 genotypes. There was however a suggestion of a role of the variant 
alleles in breast cancer development in association with smoking. An increase in breast cancer 
risk among smokers was limited to those who were variant for the CYP1A1 M1 polymorphism 
and who had smoked greater than 29 pack-years contrary to the findings of Ambrosone et al.16 
noted above.  
In a case-control study recruiting 150 postmenopausal Chinese women with breast cancer 
and an equal number of controls, Huang et al.18 found that the homozygous variant of the 
CYP1A1-MspI polymorphism was a significant predictor of breast cancer risk, independent of 
other established risk factors (adjusted odds ratio 1.98; 95% CI, 1.01-3.99). In a recent study 
among Japanese women, Miyoshi et al.19 found that carriers with variant allele 6235C (MspI 
polymorphism) or variant allele 462Val (exon 7) have significantly lower risk of breast cancer, 
that is, the ORs were 0.60 for the 6235C (MspI polymorphism) carriers and 0.66 for allele 
462Val (exon 7) carriers compared with noncarriers. They also noted linkage disquilibrium 
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 between the two variants because most of the variant 462Val carriers were associated with the 
variant allele 6235C (MspI polymorphism) carriers by haplotype analysis. These findings are 
inconsistent with those reported for other ethnicities; that is, carriers of these variant alleles have 
a breast cancer risk equivalent to noncarriers in Caucasian women13,17,28 and carriers of variant 
allele 6235C (MspI) have a significantly higher breast cancer risk than noncarriers in African-
American women13,14 and similar to the findings in postmenopausal Chinese women in Taiwan18. 
The authors admitted that reasons for their finding are currently unknown but postulated that this 
may be partly explained by the differences in other genetic and environmental factors among 
these ethnicities 
Some of the limitations of our study have to do with recall and other biases associated 
with case-control studies. However, the genetic constitution of individuals is constant and not 
susceptible to recall bias. Control subjects for our study were recruited from hospital patients; 
this group of control patients may not be exactly representative of the general population from 
which the cases were drawn. It should however be noted that with limited communication 
facilities in developing countries such as Nigeria, population controls are often difficult to 
recruit. Sample size may also be a factor of concern. Although we calculated sample size based 
on available data in the literature, some of the studies used were of small sample size and may 
not be very reliable for accurate sample size determination. Over 70% of breast cancer patients 
presented with advanced stages of the disease (Manchester Stages III and IV). It is possible that 
we may have missed patients with rapidly progressive breast cancer who may have died before 
reaching the stage of fungating tumors seen in most of our patients. There is currently no breast 
cancer-screening program in Nigeria; it is possible that we also missed patients with early stage 
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 preclinical breast cancer. We do not know how these issues may have affected our genotype 
data. 
Although we were unable to demonstrate a statistically significant association between 
CYP1A1 polymorphisms and breast cancer risk, our findings are in keeping with some reports in 
the literature17,18 and at variance with others14. It should be noted that the contribution of genetic 
variations to breast cancer risk may vary from one population to another on account of 
differences in the prevalence of various polymorphisms across populations and because our is 
the first study to report on the relationship between CYP1A1 polymorphisms and breast cancer 
risk in sub-Saharan African populations, more studies are suggested to further elucidate the 
contribution of CYP1A1 genetic variants to breast cancer risk in African populations. It is our 
hope that new techniques employing high through put microarray and proteonomic technologies 
may contribute to our understanding of the role of genetic variants to susceptibility to breast 
cancer and other malignancies in the next decades. 
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Table 4-1: CYP1A1 Polymorphisms analysis by restriction enzyme digest 
 
Polymorphism 
 
Primers 
 
Restriction 
enzyme 
 
Fragment 
 
 
M1: T6235C creates a new MspI 
site 
 
 
C1, C2 
 
MspI 
 
T (348), C (230, 118) 
 
M2: A4889G results in Ile462Val 
and may increase enzyme activity 
 
C3, C4 
 
BsrDI 
 
G (377), A (237, 240) 
 
M3: T5639C creates a new MspI 
site 
 
C5, C6 
 
MspI 
 
T (400), C (330, 70) 
 
C4887A results in Thr461Asn with 
unknown functional effect 
 
C3, C4 
 
BsaI 
 
A (377), C (227, 150) 
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Figure 4-1: CYP1A1 M1 MspI Restriction Digest 
 
 
 
Figure 4-2: CYP1A1 M2 BsrdI Restriction Digest 
84 
  
Figure 4-3: CYP1A1 M3 MspI Restriction Digest 
 
 
Figure 4-4: CYP1A1 M4 BsaI Restriction Digest 
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Table 4-2: Conditional logistic regression comparing cases and controls. Significant predictors of breast 
cancer risk [Numbers (N), Percentages (%)], [Means (S.D.)], age-adjusted odds ratio, 95% confidence 
interval 
 
Variable 
  
Cases  
 
Control  
 
 
Odds ratio 
 
95% CI 
 
Family history of 
breast cancer 
 
Yes 
 
  15   (6.00)a
 
   1    (4.00)a
 
14.99 
 
1.98,113.47 
 No 235 (94.00)a 249 (96.00)a 1.00  
 
Waist/hip ratio 
(>0.90) 
 
Yes  
 
161 (64.40)a
 
117 (46.80)a
 
2.00 
 
1.39,2.87 
 No   89 (35.60)a 133 (53.20)a 1.00  
 
Abortion 
 
Yes 
 
  18   (7.20)a
 
   7    (2.80)a
 
2.43 
 
1.01,5.85 
 No 232 (92.80)a 243 (97.20)a 1.00  
 
Age at first full-term 
pregnancy 
  
  23.18 (5.36)b
 
  21.87 (4.74)b
 
1.39 
 
1.11,1.73 
 
Education >= High 
School 
 
Yes 
 
136 (54.40)a
 
113 (45.20)a
 
1.31 
 
1.07,1.61 
 No 114 (54.60)a 137 (54.80)a 1.00  
      
 
Parity 
 
 
 
    4.1 (2.9)b
 
    4.7 (3.1)b
 
0.88 
 
0.81,0.96 
 
Duration of 
breastfeeding 
  
  65.48 (47.32)b
 
  80.96 (53.67)b
 
0.75 
 
0.62,0.91 
a: [Numbers (N), Percentages (%)], b: [Means (SD)] 
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Table 4-3: CYP1A1 M1 Allele and Genotype frequencies for Breast Cancer Study Participants 
  
Cases (n = 220) 
 
Controls (n = 218) 
 
All women 
 
  
Allele frequencies    
CYP1A1 M1 (T) 0.77 0.76 
CYP1A1 M1 (C) 0.23 0.24 
   
Genotype frequencies   
CYP1A1 M1 (T/T) 0.61 0.60 
CYP1A1 M1 (T/C) 0.31 0.33 
CYP1A1 M1 (C/C) 0.07 0.08 
   
Premenopausal women 
 
  
Allele frequencies   
CYP1A1 M1 (T) 0.78 0.75 
CYP1A1 M1 (C) 0.22 0.25 
   
Genotype frequencies   
CYP1A1 M1 (T/T) 0.62 0.57 
CYP1A1 M1 (T/C) 0.32 0.35 
CYP1A1 M1 (C/C) 0.06 0.08 
   
Postmenopausal women 
 
  
Allele frequencies   
CYP1A1 M1 (T) 0.75 0.77 
CYP1A1 M1 (C) 0.25 0.23 
   
Genotype frequencies   
CYP1A1 M1 (T/T) 0.60 0.62 
CYP1A1 M1 (T/C) 0.30 0.31 
CYP1A1 M1 (C/C) 0.10 0.07 
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Table 4-4: Distribution of genotype frequencies of the CYP1A1 M1 polymorphism in relation to breast cancer 
risk 
  
Cases 
(unmatched) 
 
Controls 
(unmatched) 
 
OR (95% CI) 
 
OR (95% CI)a 
 
 
All women 
 
    
CYP1A1 M1 (T/T) 135 (61.36) 130 (59.63) 1.00 1.00 
CYP1A1 M1 (T/C)   69 (31.36) 71 (32.57) 0.78 (0.48-1.27) 0.79 (0.46-1.40) 
CYP1A1 M1 (C/C)   16 (7.27) 17 (7.80) 0.79 (0.45-1.38) 0.91 (0.50-1.66) 
     
CYP1A1 M1 (T/T) 135 (61.36) 130 (59.63) 1.00 
 
 
CYP1A1 M1 
(T/C+C/C) 
 85 (38.63)  88 (40.37) 0.75 (0.48-1.18) 0.79 (0.48-1.29) 
 
 
Pre-menopausal 
women 
    
CYP1A1 M1 (T/T) 78 (62.40) 71 (57.26) 1.00  
CYP1A1 M1 (T/C) 40 (32.00) 43 (34.68) 0.62 (0.31-1.24)  
CYP1A1 M1 (C/C)   7 (5.60) 10 (8.06) 0.63 (0.28-1.44)  
     
CYP1A1 M1 (T/T) 78 (62.40) 71 (57.26) 1.00 
 
 
CYP1A1 M1 
(T/C+C/C) 
47 (37.60) 53 (42.74) 0.58 (0.31-1.09)  
 
 
Postmenopausal 
women 
    
CYP1A1 M1 (T/T) 62 (60.19) 58 (61.70) 1.00  
CYP1A1 M1 (T/C) 31 (30.10) 29 (30.85) 1.00 (0.49-2.05)  
CYP1A1 M1 (C/C) 10 (9.71) 7 (7.45) 1.16 (0.55-2.44)  
     
CYP1A1 M1 (T/T) 62 (60.19) 58 (61.70) 1.00 
 
 
CYP1A1 M1 
(T/C+C/C) 
41 (39.81) 36 (38.30) 1.06 (0.55-2.01)  
a: adjusted for family history of breast cancer, waist/hip ratio, age at first childbirth and 
education 
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Table 4-5: CYP1A1 M3 Allele and Genotype frequencies for Breast Cancer Study Participants 
  
Cases (n = 229) 
 
Controls (n = 227) 
 
All women 
 
  
Allele frequencies    
CYP1A1 M3 (T) 0.88 0.87 
CYP1A1 M3 (C) 0.12 0.13 
   
Genotype frequencies   
CYP1A1 M3 (T/T) 0.77 0.76 
CYP1A1 M3 (T/C) 0.23 0.23 
CYP1A1 M3 (C/C) 0.004 0.01 
   
Premenopausal women 
 
  
Allele frequencies   
CYP1A1 M3 (T) 0.87 0.85 
CYP1A1 M3 (C) 0.13 0.15 
   
Genotype frequencies   
CYP1A1 M3 (T/T) 0.75 0.71 
CYP1A1 M3 (T/C) 0.24 0.28 
CYP1A1 M3 (C/C) 0.01 0.01 
   
Postmenopausal women 
 
  
Allele frequencies   
CYP1A1 M3 (T) 0.89 0.90 
CYP1A1 M3 (C) 0.11 0.10 
   
Genotype frequencies   
CYP1A1 M3 (T/T) 0.79 0.81 
CYP1A1 M3 (T/C) 0.21 0.18 
CYP1A1 M3 (C/C) 0.00 0.01 
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Table 4-6: Distribution of genotype frequencies of the CYP1A1 M3 polymorphism in relation to breast cancer 
risk 
  
Cases 
(unmatched) 
 
Controls 
(unmatched) 
 
OR (95% CI) 
 
OR (95% CI)a 
 
 
All women 
 
    
CYP1A1 M3 (T/T) 176 (76.86) 172 (75.77) 1.00 1.00 
CYP1A1 M3 (T/C) 52 (22.71) 53 (23.35) 0.95 (0.62-1.47) 0.76 (0.47-1.22) 
CYP1A1 M3 (C/C) 1 (0.44) 2 (0.88) 1.00 (0.25-4.00) 1.95 (0.24-6.01) 
     
CYP1A1 M3 (T/T) 176 (76.86) 172 (75.77) 1.00 
 
 
CYP1A1 M3 
(T/C+C/C) 
53 (23.14) 55 (24.23) 0.95 (0.62-1.46) 0.76 (0.47-1.22) 
 
 
Pre-menopausal 
women 
    
CYP1A1 M3 (T/T) 95 (75.40) 90 (71.43) 1.00  
CYP1A1 M3 (T/C) 30 (23.81) 35 (27.78) 0.81 (0.45-1.44)  
CYP1A1 M3 (C/C) 1 (0.79) 1 (0.79) 1.00 (0.25-4.00)  
     
CYP1A1 M3 (T/T) 95 (75.40) 90 (71.43) 1.00 
 
 
CYP1A1 M3 
(T/C+C/C) 
31 (24.60) 36 (28.57) 0.82 (0.46-1.43)  
 
 
Postmenopausal 
women 
    
CYP1A1 M3 (T/T) 81 (78.64) 80 (80.81) 1.00  
CYP1A1 M3 (T/C) 22 (21.36) 18 (18.18) 1.06 (0.54-2.10)  
CYP1A1 M3 (C/C) 0 (0.00) 1 (1.01)    -  
     
CYP1A1 M3 (T/T) 81 (78.64) 80 (80.81) 1.00 
 
 
CYP1A1 M3 
(T/C+C/C) 
22 (21.36) 19 (19.19) 1.06 (0.54-2.10)  
a: adjusted for family history of breast cancer, waist/hip ratio, age at first childbirth and 
education  
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GENERAL DISCUSSION/FUTURE RESEARCH 
 
A rapidly growing global population, an aging world population profile with changing 
reproductive characteristics, a western-oriented diet heavily laden with animal fat, a sedentary 
lifestyle and a work environment exposed to various chemical carcinogens have all contributed 
partly to the rising global burden of breast cancer, a disease predominantly affecting the worlds’ 
female sex. Breast cancer is the third most frequent cancer in the world (796,000 cases in 1990) 
and by far the most common malignancy of women (21% of all new cases). Worldwide, the ratio 
of mortality to incidence is about 61% (Parkin et al., 1999a). As a result, breast cancer ranks as 
the fifth cause of death from cancer overall, although it is still the leading cause of cancer 
mortality in women (the 314,000 annual deaths represent 14.1% of cancer deaths in females). 
Recent World Health Organization (WHO) statistics indicate that with an annual incidence rate 
increase of about 0.5% in western countries, and rates as high as 5% in China and other Eastern 
Asian countries and probably similar increases in sub-Saharan Africa and South America, the 
global burden of breast cancer in 2010 would be 1.45 million new cases, an 82% increase over 
the figure in 1990 (Parkin et al., 1999a). This increasing disease burden, likely to be born by the 
dwindling economies of the developing countries with the least resources to fight the disease 
calls for a reawakening of global efforts to combat the disease. We may not be able to 
completely eliminate breast cancer, but emerging evidence from the developed world provide 
evidence that we can at least slow the growth in the incidence of the disease and reduce 
morbidity and mortality in those afflicted by breast cancer. 
Globally the prognosis for breast cancer is reported as generally rather good. The highest 
crude survival is reported by the SEER program, 84%, consistent with the age-adjusted estimate 
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 for North America of 73%. Survival rates are high in Japan (74%) and Australia/New Zealand 
(68%) and lower in Europe (53% to 63%, consistent with the EUROCARE crude rate of 67%). 
Elsewhere survival ranges from 49% to 61% (Parkin et al., 1999a). 
 An issue of concern to the US in particular is the Black/White disparities in breast cancer 
burden within the US. Although, there are conflicting reports in the literature as to the degree of 
this disparity accounted for by racial differences in socioecomonic status, mammographic 
screening, and access to health care, there appear to be a consensus that a certain proportion 
remains explained by race. Black women diagnosed with breast cancer experience a 5-year 
relative survival of only 62%, compared with 79% for white women (Miller et al., 1992). Part of 
the poorer breast cancer survival for black women is due to more, advanced stage of disease at 
presentation, but some analyses that have controlled or stratified for stage have still found black 
women’s survival to be poorer than that of their white counterparts (Rain et al., 1986; 
McWhorter et al., 1987; Kimmick et al., 1991; Fisher et al., 1993). Research concerning 
differences in breast cancer survival between black and white women suggests that the biological 
characteristics of tumors may differ between the races (Fisher et al., 1993; Dayal et al., 1982). 
Recent data from the National Cancer Institute Black/White Cancer Survival Study showed that 
after adjusting for stage, treatment, comorbid illness, and pathologic and sociodemographic 
variables, blacks continued to demonstrate a slightly increased, but not statistically significant, 
risk of death (hazard ratio=1.3; 95% CI 1.0-1.8) (Eley et al., 1994). Current efforts to eliminate 
health disparities among the different racial groups in the US will help show whether or not this 
Black/White differences will remain in the next decades to come. 
 A coalition of global efforts based upon sound public health principles and led by 
epidemiology hold the key to success in the fight to reduce the global burden of breast and other 
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 cancers. The last half-century has seen the integration of disciplinary efforts to better understand 
the process of carcinogenesis. Recent advances in the traditional disciplines of bacteriology, 
virology, biochemistry and molecular biology and rapid progress in the Human Genome Project, 
and the application of tools of molecular biology to epidemiological studies will markedly 
influence the road map in the search for etiologic factors for breast cancer. For these efforts to 
have lasting impact on reducing global breast cancer burden, epidemiological research has to 
adopt a global approach. This is because there is evidence supporting a multifactorial etiology 
for breast cancer. In fact, it is being speculated that breast cancer is not a single disease entity but 
a final common pathway for the manifestation of a variety of genetic insults resulting in loss of 
cellular regulation and integration. While breast cancer occurs in all continents and countries 
across the globe, it is the nature of the disease that risk factors may differ from one part of the 
world to the other. Available data suggests that reproductive characteristics such as age at 
menarche, parity, duration of breastfeeding and practices such as use of exogenous estrogens for 
birth control and hormone replacement therapy (HRT) differ considerably between the 
developed world and developing countries(Collaborative Group on Hormonal Factors for Breast 
Cancer, 1997). In addition, prevalence of obesity (a risk factor associated with many chronic 
diseases including breast cancer) varies widely across the globe.  
 The choice of Nigerian women for this study was meant to serve dual purposes.  
Sub-Saharan Africa, of which Nigeria (population: 130 million) (Nigeria National Population 
Commission, 2003) is one of the component countries, is a region of the world grossly under-
represented in the epidemiologic literature. Until recently, it used to be said that breast cancer 
was very rare in Nigeria; simply because the disease has not be adequately studied in the 
population. We believe that studying breast cancer risk factors among Nigerian women will not 
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 only provide data about the disease among populations in sub-Saharan Africa but will contribute 
to global efforts at control and prevention. In addition, there is evidence that the Nigerian 
population under study share considerable genetic ancestry with Nigerian women. We suspect 
that predictors of breast cancer risk particularly genetic risks may be similar in the two 
populations. Studying breast cancer risk among African American women in the US has been 
hampered by low participation rate which has been attributed to factors such as mistrust and 
suspicion of the healthcare system, economic limitations, low level of education, concerns about 
drug toxicity, cultural/religious beliefs/attitudes, poor access to health care, lack of awareness 
about studies, past negative experiences, and physicians’ attitude (Cox et al., 1998; Harris et al., 
1996; Shavers-Hornaday et al., 1997; Swanson et al., 1995; Thomas et al., 1994; Robinson et al., 
1996). Studying the role of low-penetrance genes such as cytochrome P450 (CYP1A1) and 
catechol-O-methyltransferase (COMT) gene polymorphisms in breast cancer susceptibility in 
Nigerian women provides an excellent opportunity for investigating the contribution of genetic 
factors to breast cancer burden in populations of African descent. The high participation rate of 
the study population is encouraging although infrastructural inadequacy creates setbacks in the 
conduct of such studies.  
 
Article 1 
The first article evaluates the descriptive epidemiology of breast cancer risk in the study 
population. Breast cancer in our study population was found to be predominantly premenopausal 
(56.8%). Risk factors associated with increased risk of breast cancer in our study population 
include family history of breast cancer, higher waist/hip ratio, abortion, age at first full-term 
pregnancy, and higher level of education while increasing parity and longer duration of 
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 breastfeeding conferred protection against the disease. These findings are similar to 
characteristics of the disease reported in studies comparing the risk profiles of breast cancer in 
African American and Caucasian women in the US. African American women under the age of 
45 years have a greater incidence of breast cancer than Caucasian women in this young age 
range. These rates equalize during the fifth decade of life, and for women over the age of 55 
years, incidence rates for Caucasian women surpass those of African Americans (Newman, 
2005). Available clinical data indicate that 30%-40% of African American breast cancer patients 
seen in clinical practice are younger than 50 years, compared with 20% of Caucasian breast 
cancer patients in this age range (National Cancer Data Base, 1994). Factors accounting for this 
race-related risk profile are not clearly understood.  
In a landmark study, Pike et al (1983) proposed the model of “breast tissue age” and this 
has been supported by a further extension of the Pike model by Pathaks and Whittemore (1992). 
The theory of Pike assumes that breast carcinoma vary in proportion to a power of the 
accumulated “breast tissue age” (Pike et al., 1983). In that model, the breast tissue ages at a 
constant rate between age at menarche and age at first full-term pregnancy (FFTP), at which time 
the hormonal milieu of pregnancy causes a one-time increase in breast tissue age but lowers the 
rate of subsequent “breast tissue aging”. This lower rate continues until the perimenopausal 
years, at which time it decreases linearly until menopause. After menopause the breast tissue 
continues to age, but at a much lower rate. This model predicts that at a given age, a woman with 
an FFTP in the preceding 5-10 years is at increased risk relative to a nulliparous woman. Studies 
of Janerich and Hoff (1982), and Pathak et al (1986) have confirmed this theory. Carrying a 
pregnancy to the third trimester confers a protective effect on lifetime risk for breast carcinoma if 
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 that pregnancy occurs early in life. However, if a woman delivers her first child close to the age 
at which menopause occurs, her lifetime risk is actually higher than if she was nulliparous. 
 Pathaks and Whittemore (1992) extended Pike’s single-birth model to a multiple birth 
model, by incorporating a smaller increase in risk at each additional full term pregnancy with a 
subsequent lowering of the rate at which breast tissue ages. Rosner et al (1994) fitted the 
extended Pike model to prospective data from the Nurse’s Health Study and obtained breast 
carcinoma incidence curves for various combinations of age at FFTP, total parity, and ages at 
subsequent births. The predicted incidence curves for these hypothetical scenarios show lower 
risk for nulliparous women relative to multiparous women until ages 42-45 years, at which time 
a crossover occurs and the multiparous are at lower risk relative to the nulliparous women. The 
crossover for women with a single birth at age 20 years does not occur until age 55 years. This 
shift to a later age for the crossover effect for women with a single birth relative to multiparous 
women would be expected based on the hypothesized decreased rate of breast tissue aging after 
each subsequent pregnancy (Pathak et al., 2000). 
 Another factor that may contribute to higher breast cancer risk in young black women is the 
higher rate of abortions performed before the first full-term pregnancy and higher rate of use of oral 
contraceptive pills during the same period compared to young white women (Romieu et al., 1990). 
Although abortion was associated with increased risk of breast cancer in our patients, the abortion 
rates were low and data is lacking on the number of abortions performed before first full-term 
pregnancy in our patients. Increasing incidence of abortion and use of oral contraceptives among the 
younger cohorts of Nigerian women is of concern to the risk of breast cancer in the population in the 
future. Of concern also is the changing lifestyle of the younger cohorts of Nigerian women. 
Increasing westernization with more consumption of animal fat and sedentary lifestyle may lead to 
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 obesity epidemic in the future as is being witnessed in the developed world. In addition, early 
menarche, delay in childbearing and reduced parity may add to drive up longer period of lifetime 
unopposed estrogen exposure (an established risk factor for breast cancer). 
 
Article 2 
 In the second article, we evaluated the association between the G to A transition 
polymorphism in codon 158 of the COMT gene and breast cancer risk in the study population. In 
the final conditional logistic regression model controlling for identified risk factors for breast 
cancer, harboring at least one low-activity COMT (Met) allele was associated with a significant 
43% reduced risk of breast cancer (OR = 0.57, 95% CI 0.36-0.91). Similar reduced risks were 
observed in both premenopausal and postmenopausal breast cancer risk although further 
subgroup analysis were precluded by the low frequency of the COMT (Met) allele in the study 
population. We noted a 2 times lower frequency of the COMT (Met/Met) compared with the 
13% reported in African Americans and 3-4 times lower than the 22-28% in Caucasians 
(Millikan et al, 1998). Our finding of reduced risk of breast cancer both in the final conditional 
logistic regression multivariate model and in univariate analyisis in premenopausal and 
postmenopausal women agrees with the 20% reduced risk (although not significant) in both 
premenopausal and postmenopausal African American women and the 20% and 30% reduced 
risk (also not significant) of premenopausal and postmenopausal breast cancer risk among 
Caucasian women reported by Millikan et al (1998). The findings of 2-fold increased risk (not 
significant) of postmenopausal breast cancer among Caucasian women by Lavigne et al. (1997) 
and 5.7 fold increased risk of premenopausal breast cancer risk in Caucasian women by 
Thompson et al. (1998) is contrary to our findings. As noted previously, Asian women appear to 
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 show a more consistent increased risk of breast cancer in carriers of the low-activity COMT 
(Met) allele (Yim et al., 2001).  
Factors responsible for the inconsistencies in the reports in the literature with respect to 
association studies of the codon 158 COMT polymorphism are not easy to explain. For example, 
how do we explain the protection conferred by the COMT gene variant for breast cancer in our 
study subjects. In the first instance, this finding is contrary to our hypothesis of increased breast 
cancer risk among carriers of the variant allele because of the known functions of the COMT 
gene and the reported decreased methylation activity of the gene caused by the codon 158 
polymorphism. We have already noted the much lower frequency of the COMT (Val/Met) and 
COMT (Met/Met) variants in our population compared with Caucasians. This reduced frequency 
of the variant allele might suggest a smaller impact of this polymorphism on the methylation of 
estrogen catechols in our subjects. Another possible explanation for our finding may be that the 
codon 158 Valine/Methionine polymorphism is in linkage disequilibrium with other 
polymorphisms of functional significance in the detoxification of biologically harmful estrogen 
catechols. We noted that sample size impacted subgroup analysis in our study. Although, our 
sample size of 231 cases and 229 controls with successful genotype data is larger than the sample 
size reported in most of the other studies noted above, the lower prevalence of the COMT 
(Met/Met) genotype in our population implies the need for larger sample size to be able to detect 
similar sizes of effects noted in either Caucasian or African American women. Using our COMT 
(Met/Met) frequency of 0.07 detected in our control subjects will require a sample size of 304 
premenopausal cases and 304 premenopausal controls if we wish to detect an odd ratio of 2.4 
(reported by Thompson et al., 1998). Our sample size of 142 premenopausal cases and 142 
premenopausal controls is just about half the calculated sample size. Sample size is always an 
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 issue of contention in early studies in population groups with no pre-existing data and our 
experience with the COMT gene highlights the importance of prior pilot studies. Our finding will 
serve this purpose for future disease association studies of this polymorphic variant in the 
Nigerian population. 
Efforts to explain the discrepancy between the protective effect reported by Millikan et al. 
(1998) and the increased risk reported by Lavigne et al. (1997) and Thompson et al. (1998) (both 
reports contrasting with each other) among Caucasian women in the US have been less rewarding. 
As noted by Thompson et al. (1998), one possible explanation for the inconsistencies may be 
differences in the ethnic backgrounds of study participants. It should be noted that Caucasian 
Americans are of different European ethnicities which may affect the distribution of the COMT 
variant genotypes, a factor that can partly account for the divergent findings. Differences in these 
findings may also be the result of small sample size of the studies. As noted previously, the study of 
Lavigne et al. (1997) had only 113 cases and 113 controls in contrast to that of Thompson et al. 
(1998) (281 cases and 289 controls) and Millikan et al. (1998) (Caucasians: 389 cases and 379 
controls, African Americans (265 cases and 263 controls). Another possible explanation may be the 
action of other compensating enzymes such as Glutathione S-transferase (GSTs), uridine diphospho-
glucuronosyltransferase (UGT) 1A1, and the highly polymorphic manganese superoxide dismutase 
(MNSOD) genes that are induced when COMT activity is very low. Lower oxidative damage in the 
presence of COMT-(Met/Met) genotype may also be of importance; the level of 8-hydroxy-2’-
deoxyguanosine in breast tissue was higher in patients with COMT (Val/Val) genotype as shown by 
Markides et al. (1998). 
 The fact that the COMT gene is highly polymorphic in some populations means that the 
population attributable risk for breast cancer resulting from the COMT genetic polymorphism may 
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 be more marked in populations of higher prevalence of the homozygous COMT (Met/Met) genotype 
such as Caucasian populations (Millikan et al., 1998) compared with effects on risk in populations of 
lower prevalence as demonstrated in the Nigerian population and in Asian populations (Yim et al., 
2001). In addition, environmental factors such as the prevalence of obesity in the population may 
also modulate the effect of the genotype on breast cancer risk. The implication of the above is that as 
part of the global strategy for the control and prevention there is need for studies of the prevalence of 
these polymorphisms in diverse population groups across the world to properly define the role of the 
COMT gene in breast cancer risk in various populations. 
 
Article 3 
Our interest in the third article is to assess the role of four polymorphic variants (M1, M2, 
M3, and M4) in the cytochrome P450 (CYP1A1) gene in breast cancer susceptibility. CYP1A1 is 
involved in the 2-hydroxylation of estrogens to 2-hydroxy catechol metabolites for subsequent 
O-methylation to 2-methoxy derivatives including 2-methoxyestradiol. There is currently little 
information on the activities of these various polymorphic variants in the CYP1A1 gene in 
human populations, efforts are underway to characterize the biochemical properties of these 
variants to enhance research into their possible role in disease risk. There is evidence suggesting 
enhanced hydroxylation activity for the exon 7 polymorphism in some populations such as the 
Japanese (Nakachi et al., 1993) but not in African Americans (Taioli et al., 1995). This study has 
demonstrated the high prevalence of the CYP1A1 M1 and CYP1A1 M3 variants and the rarity of 
the CYP1A1 M2 and CYP1A1 M4 polymorphims in the Nigerian population. The CYP1A1 M1 
(C/C) genotype frequency of 8% was found to be twice the 3.5% reported in African Americans 
but about 3-4 times higher than the 2% noted in Caucasians (Taioli et al., 1995). Our finding of a 
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 non-significant 19% reduced risk of breast cancer in our study subjects is in sharp contrast to the 
almost 10 times increased risk reported by Taioli et al. (1995) in African Americans although it 
must be pointed out that their small sample size of 21 cases and 85 cases creates room for 
spurious associations. Also, the finding of a significant 1.98 times increased risk of 
postmenopausal breast cancer risk in Chinese women in Taiwan (Huang et al., 1999) contradicts 
our finding of a non-significant 16% increased risk of breast cancer in postmenopausal women in 
our study. The finding of significant 40% and 42% reduced risk of breast cancer among Japanese 
women harboring the heterozygous and homozygous variants of this genotype respectively 
(Miyoshi et al., 2002) also reflects the inconsistencies associated with association studies 
between CYP1A1 M1 variant and breast cancer risk in various populations. It must however be 
appreciated that the 51% CYP1A1 M1 (T/C) heterozygosity and the 17% CYP1A1 M1 (C/C) 
homozygosity reported among Japanese patients is about twice the frequency of these genotypes 
in the Nigerian population.  
Allele frequencies for the CYP1A1 M3 (T) and CYP1A1 M3 (C) alleles among our study 
participants was slightly lower than the figures reported by Crofts et al. (1993) among African 
American women. The CYP1A1 M3 variant is said to be African American-specific and has not 
been reported in Caucasians. We were unable to demonstrate any significant association between 
this novel polymorphism and breast cancer risk overall or in subgroup analysis in keeping with 
the findings of Taioli et al. (1995) who first described this variant in African American women 
although we noticed a higher frequency of the heterozygous CYP1A1 M3 (T/C) genotype 
compared with the figure reported by these investigators. We were unable to compute risks 
associated with the CYP1A1 M2 (Exon 7) and CYP1A1 M4 polymorphic variants due to their 
rarity in our population. 
105 
 The interest in the 2-hydroxylation of estrogens has heightened with the recent finding 
that 2-methoxyestradiol, the O-methylation product of this pathway possesses anti-tumor 
properties. 2-Methoxyestradiol inhibits the proliferation of several cancer cell lines in vitro 
(Fotsis et al., 1994), and human breast cancer cell lines (estrogen receptor positive or negative) 
were particularly sensitive to a cytotoxic effect of 2-methoxyestradiol (Cushman et al., 1995). 
Additional studies indicated that 2-methoxyestradiol disrupted microtubule function and was a 
potent inhibitor of angiogenesis (Fotsis et al., 1994). By altering microtubule stability, inducing 
apoptosis and inhibiting angiogenesis in tumor cells and downregulating cytokine and PGE2 
induced in-situ aromatase synthesis in the breast (Purohit et al., 1999), 2-methoxyestradiol 
distinguishes itself as the new focus for new generation anti-cancer chemotherapy for both 
hormone dependent and hormone-independent breast cancer. In fact, 2-methoxyestradiol is 
undergoing a phase I trial as an angiogenesis inhibitor and search is ongoing for synthetic 
derivatives of this metabolite for anti-cancer chemotherapy (Brem et al., 1987). 
Knowledge of estrogen metabolism has also provided new insight in appreciating the 
interaction between obesity and high fat diet in mediating breast carciongenesis. It is now well 
documented that lean women or women on low fat diets have a lower risk of breast cancer than 
obese women or women consuming high fat diets. This finding is explained by the fact that in 
lean women or those on low fat diets, metabolism of estrogens via the 2-hydroxylation pathway 
predominates with subsequent formation of 2-methoxyestrogens (Longcope et al., 1987). 
Consequently, this causes downregulation of cytokine and PGE2 receptors in breast adipose 
stromal cells and reduces in situ estrogen synthesis via peripheral aromatization. In contrast, in 
obese women or subjects on high fat diets that are associated with reduced synthesis of 2-
methoxyestrogens, any cytokines or PGE2 within the breast could result in increased production 
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 of estrogens and subsequent risk of tumor development. There is also evidence suggesting that 
pesticides, which have been implicated in breast cancer, can also decrease estrogen 2-
hydroxylation but increase 16-[alpha]-hydroxylation (Bradlow et al., 1995). 
 Some of the limitations of this study include recall and other biases associated with case 
control studies although it must be noted that genotype data is constant and unlikely to be 
affected by problems with recall. We calculated sample size for this study based on data on 
African American women; the genotype frequencies used for the calculation are similar to our 
findings among the Nigerian patients. Based on the genotype frequencies of the CYP1A1 M1 
variant, we estimated that 35 CYP1A1 M1 (C/C) homozygous cases and controls would be 
required to demonstrate the odds ratio of 9.7 noted by Taioli et al (1995). Among our 220 cases 
and 218 control subjects with successful PCR-based RFLP assay, the number of cases and 
controls with the homozygous CYP1A1 M1 (C/C) genotype were 16 and 17 respectively, about 
half of the number calculated above. If the risk profile associated with the CYP1A1 M1 
polymorphism reported by Taioli et al. (1995) were to be correct, we would have required twice 
our current sample size of 220 cases and 218 controls to detect similar effect size found in their 
study. However, the sample size of 21 cases and 85 controls recruited by Taioli et al. (1995) 
seem too small for conclusive statements to be made. In addition, theirs was probably the only 
study of the association of this polymorphism with breast cancer risk in populations of African 
descent.  
 To the best of our knowledge, ours is the first study to investigate the association between 
CYP1A1 genetic polymorphisms and breast cancer risk in indigenous African women. We have 
provided baseline data with which future studies can be compared. The distribution of the 
genotype frequencies of the CYP1A1 variants reported here will provide the basis for estimating 
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 sample sizes required for further studies on the role of these variants on breast cancer risk in sub-
Saharan African populations. 
 
Future Research 
This study has provided us opportunity for an exploratory study to investigate the risk 
factors for breast cancer in Nigerian women, a population of exclusively indigenous African 
women, a population about whom little is known about breast cancer susceptibility. We have had 
a lot of difficulties; however we have learnt a lot of lessons within the past 3 years of this study. 
First, because of the multicenter design, we have been able to establish loci for future research on 
breast and other cancers within the Nigerian population. We have shown in the first article on the 
descriptive epidemiology of breast cancer in the population that reproductive variables and other 
factors similar to reports in other populations predict breast cancer risk in this population, thus 
establishing that lifetime estrogen exposure remains the main arbiter of breast cancer risk in 
indigenous African women as in other populations. Our exploratory data on the association 
between the COMT and CYP1A1 genetic polymorphims and breast cancer risk in these women 
has provided a reference on which future studies would depend. We have pointed out limitations, 
which might have affected our results, and we hope to avoid them in future studies. The rapid 
progress of the Human Genome Project and accompanying fascinating progress in the health 
sciences including molecular epidemiology, molecular biology, genetic engineering, biostatistics 
and computer science and clinical medicine in the past half-decade has created an avalanche of 
opportunities for integrated efforts in the battle against breast cancer. Although it is becoming 
obvious that disease association studies based on single nucleotide polymorphisms are falling out 
of favor in molecular epidemiologic research, such studies have provided the impetus for the 
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 future. We are moving to a stage where hard science combined with high through put research 
tools including microarray techniques and proteomics technology will drive the search for 
etiological factors in cancer and other chronic diseases. We hope to remain in the team of the 
future by building on the foundation provided by this exploratory study.  
 As a preliminary follow up to this study, we hope to further explore the association 
between CYP1A1 genetic polymorphisms and breast cancer risk using the haplotype approach 
combining allele and genotype data for CYP1A1 M1, CYP1A1 M2, CYP1A1 M3, and CYP1A1 
M4 derived from this study. We also hope to apply the same technique in evaluating the 
association between CYP1B1 M1, CYP1B1 M2, CYP1B1 M3, and CYP1B1 M4 polymorphic 
variants of the cytochrome P4501B1 (CYP1B1) gene and breast cancer risk in this population. 
We have generated allele frequency and genotype data for the tetranucleotide simple tandem 
repeat polymorphism in the 3’ noncoding region of the aromatase gene. We will also evaluate the 
association between repeats lengths and breast cancer risk in our study population. By combining 
the genotype and haplotype data, we hope to build a multigenic model of breast cancer risk in 
these subjects. Polymorphisms in other relevant genes in the pathway of estrogen synthesis and 
metabolic pathway including the CYP17 beta-hydroxysteroid dehydrogenase (CYP17), 
cytochrome P450 3A4 (CYP3A4), glutathione-S-transferase (GSTs), uridine diphospho-
glucuronosyltransferase (UTG) 1A1, N-acetyltransferases (NATs) and manganese superoxide 
dismutase (MNSOD) genes will be investigated as part of the ongoing study. We will also 
examine polymorphisms in the estrogen receptor polymorphisms and variations in DNA repair 
genes including XRCC1, and the effect of epigenetic modifications such as promoter 
hypermethylation of various genes in transcriptional silencing and how this relates to breast 
cancer risk. As mentioned previously, there is need to expand the sample size of our study to 
109 
 increase its robustness for multigenic modeling. We hope to achieve this by recruiting more 
study participants from the Nigerian institutions; a sample size of 1000 cases and 1000 control 
subjects is being estimated for this future study. We hope to expand our capacity for robust 
comparisons by collaboration with other investigators with similar interests working with US 
populations as well as populations of African descent in the Caribbean. 
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PUBLIC HEALTH SIGNIFICANCE OF STUDY 
 
This study was focused on identifying risk factors for breast cancer in Nigerian women, 
an indigenous sub-Saharan African population. The results have demonstrated that 
sociodemographic characteristics, reproductive variables and anthropometric measures are 
significant predictors of breast cancer risk in the study population. In particular, family history of 
breast cancer in first- and second-degree relatives, higher level of education, waist/hip ratio, 
abortion and later age at first full-term pregnancy were associated with increased risk of breast 
cancer while high parity and long duration of breastfeeding conferred protection against the 
disease in Nigerian women. We further evaluated the contribution of polymorphisms in catechol-
O-methyltransferase (COMT) and cytochrome P450 1A1 (CYP1A1) genes in breast cancer 
susceptibility among the study population. Our results provide evidence suggesting that 
harboring at least one low activity COMT (Met) allele of the codon 158 Valine to Methionine 
polymorphism of the COMT gene significantly reduced the risk of breast cancer. The study also 
demonstrated the rarity of the CYP1A1 M2 and CYP1A1 M4 polymorphisms of the CYP1A1 
gene in the study population. Although the CYP1A1 M1 and CYP1A1 M3 genes were found to 
be highly polymorphic, we were unable to demonstrate significant association between these 
polymorphisms and breast cancer risk in the study population.  
While these variables are similar to the risk factors for breast cancer described in African 
American women and US Caucasians and other populations across the globe, we recognized 
notable exceptions. Firstly, there was a preponderance of premenopausal breast cancer among 
the study population similar to the distribution of the disease in African American women but in 
contrast to the higher proportion of postmenopausal breast cancer in Caucasian populations. 
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 Secondly, the use of oral contraceptives and postmenopausal hormone replacement therapy was 
very low among the Nigerian women in this study in contrast to the higher figures reported in 
Western populations. Thirdly, the Nigerian women in this population were predominantly lean 
population with mean body mass index (BMI) below figures reported in the developed countries. 
Fourthly, the frequency of the COMT (Met) allele of the codon 158 polymorphism (Valine to 
Methionine substitution) of the COMT gene was lower in our study population compared to 
figures reported in African American women and Caucasians in the US. Also the proportion of 
the homozygous genotype of the African American-specific CYP1A1 M3 polymorphism of the 
CYP1A1 gene was found to be higher in the Nigerian population than the reported figures in 
African American women. 
 Although, it is consolatory to note that the epidemic of global obesity has not spread to 
sub-Saharan Africa, there is need for policy guidelines necessary to prevent the obesity 
phenomenon from spreading to the developing countries. In addition, the adoption of abortion as 
means of family planning should be discouraged; effort should be directed to alternative methods 
that do not endanger the life of women through increasing breast cancer risk. Also, physical 
inactivity appear to be creeping into the lives of populations of developing countries as sedentary 
office jobs replace the traditional agrarian economies. Alcohol consumption and cigarette 
smoking rates although low in the study population are likely to be on the increase in these 
populations in this century. Both factors have been linked to increased risk of breast cancer in 
developed Western populations. The global anti-smoking campaign should be expanded to the 
developing countries as the Tobacco companies shift their operations to these countries.  
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Overall, the findings of this study has contributed to knowledge about risk factors for 
breast cancer in populations of African ancestry in general and Nigerian population in particular 
and has provided baseline data for future epidemiologic studies in sub-Saharan African 
populations. 
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SUMMARY 
 
The study titled “Estrogens, Genetic Polymorphisms and Breast Cancer Risk in Nigerian 
Women” was designed to evaluate the role of reproductive variables (surrogate measures of 
lifetime estrogen exposure), family history, anthropometric variables and genetic polymorphisms 
in breast cancer susceptibility in Nigerian women. The first article of the study evaluated the 
descriptive epidemiology of breast cancer. Two hundred and fifty women with histologically-
confirmed breast cancer and their age matched controls were recruited from four University 
Teaching Hospitals in Midwestern and Southeastern Nigeria for the study. Recruitment was 
successfully conducted during a 20-month period between September 2002 and April 2004. The 
association between various reproductive variables, sociodemographic characteristics and 
anthropometric measurements and breast cancer risk in the study population was assessed using 
conditional logistic regression models.  
Results showed that a positive family history of breast cancer was associated with 
increased risk of breast cancer. Higher level of education above High School also increased the 
risk of breast cancer in these women. While reproductive variables such as late age at first full-
term pregnancy and abortion were associated with increased risk of breast cancer, high parity 
and long duration of breastfeeding were protective against the development of the disease. 
Among the anthropometric measurements evaluated for association with breast cancer risk, only 
waist/hip ratio was found to be significantly associated with increased breast cancer risk. The 
population was found to be lean with mean body mass index (BMI) below figures reported in 
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 most Western populations. Although there was a tendency towards increased risk with increasing 
height, the difference did not attain statistical significance. 
The second article was designed to investigate the hypothesis that harboring the low-
activity COMT (Met) allele of the codon 158 valine to methionine substitution polymorphism of 
the catechol-O-methyltransferase (COMT) gene will increase the risk of breast cancer. Although 
biological samples were obtained from the 250 women with breast cancer and the 250 age-
matched controls recruited from the Nigerian institutions, the polymerase chain reaction (PCR)-
based restriction length polymorphism (RFLP) assay was successful in 231 cases and 229 control 
subjects. It was found that the frequency of the COMT (Met) allele was lower in the Nigerian 
study population with a correspondingly higher prevalence of the COMT (Val) allele compared 
to the reported distribution of these alleles in both African American and Caucasian women in 
the US. After controlling for risk factors for breast cancer identified in the descriptive analysis, it 
was found that harboring at least one low activity COMT (Met) allele of the COMT 
polymorphism (COMT valine to methionine substitution in codon 158) was associated with 
significant decrease in breast cancer risk in the final multivariate logistic regression model. 
Although, this is contrary to our initial hypothesis, we speculate that this polymorphism may be 
in linkage disequilibrium with other yet to be identified polymorphisms that might be associated 
with reduced breast cancer risk in our study population. 
The third article investigated the association between four polymorphisms in the 
cytochrome P450 1A1 (CYP1A1) gene and the risk of breast cancer in the study population 
using a PCR-based RFLP assay. The assays were successful in 220 cases and 218 controls. 
While the CYP1A1 M1 and CYP1A1 M3 polymorphisms were found to be common in our study 
populations, the CYP1A1 M2 and CYP1A1 M4 variants were found to be very rare as only one 
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 control subject carried the heterozygous CYP1A1 M2 (A/G) genotype. All the study participants 
were homozygous for the CYP1A1 M4 (C) allele. 
A conditional logistic regression model was used to evaluate the association between 
these polymorphisms and breast cancer risk. We were unable to demonstrate significant 
association between the CYP1A1 M1 and CYP1A1 M3 polymorphisms and breast cancer risk, 
both overall and in subgroup analysis based on menopausal status. We however noted a higher 
frequency of the African American-specific CYP1A1 M3 (C) allele in our study subjects 
compared with reported figures in African American women. 
Results of this study have important public health implications. First, it has provided 
evidence for a role for reproductive and sociodemographic variables in susceptibility to breast 
cancer in indigenous African women; thus contributing to the global epidemiologic literature on 
risk factors for breast cancer in populations of African ancestry. It has also provided data 
suggesting protection for breast cancer for women harboring at least one low activity COMT 
(Met) allele of the COMT gene. As noted previously, the study provides baseline data that will 
serve as an important resource tool for similar epidemiologic studies in sub-Saharan African 
populations. In particular, it provides genotype data for the determination of sample size in 
studies evaluating the role of polymorphisms in the COMT and CYP1A1 genes and breast cancer 
risk. In addition, the findings of this study will serve a useful resource tool in policy decisions 
aimed at breast cancer control and prevention in these populations. 
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APPENDIX A: STUDY QUESTIONNAIRE 
 
 
 
Date ____/____/_____     ID No. NB02 __ __ __ __ __ __ __ 
        Day   Mon  Year                                                              IRB # 010767  
                                                                                                  Approved _08_/28/_01__ 
                                                                                                 Renewal   08/27/ 02     
Data Status: 
 
1. Final complete________    2. Final incomplete______   
 
 
ESTROGENS, GENETIC POLYMOPHISMS AND BREAST CANCER RISK 
 Baseline Questionnaire 
 
Consent form signed: 1.  No ___ 2.  Yes ___      
 
IF NO, DO NOT PROCEED UNTIL STUDY HAS BEEN EXPLAINED AND CONSENT FORM HAS BEEN 
SIGNED. 
 
Please complete: 
 
(Note: You need not answer questions you feel uncomfortable answering) 
 
 
Date of Birth:  _____/_____/______   
   Day      Month     Year 
 
 
Do you wish to participate in this study? 
 
1. No ___  2.  Yes ___ 
 
If yes, previously diagnosed with breast cancer 1.  No ___ 2.  Yes ___    ____ 
 
 
Status: 1. Agrees to participate 2.  Undecided/postponed  3. Withdrawn  _____ 
 
 
 
 
FOR OFFICE USE ONLY 
 
Interviewer ID# ____________ Nigerian referral source            ___ ___ 
 
Data Entry Date  (1) ____/____/____ Data Entry ID# _________ 
           (2) ____/____/____ 
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ID No. NB 02__ __ __ __ __ __ __ 
 
THE FOLLOWING QUESTIONS ASK ABOUT YOUR GENERAL BACKGROUND, WORK HISTORY, AND 
SMOKING HISTORY. 
 
 
1.  Place of Birth - Country of Birth?   ___________________________________________ 
  
  
2a. What tribe/ethnic group are you?   
Edo Bini/Benin___ E.Ishan___E.Ora/Owan___E.Etsako/Afemai___E.Akoko___Urhobo___ 
Itsekiri___Ijaw/Izon___Ibo Bendel___I.Imo/Anambra/Ebonyi/Abia___Efik___Kalabari___ 
Yoruba___Other(Specify)___ 
 
2b. What is your religion?__________________________________  
  
3.  What is the highest grade or level of schooling you completed?  (Mark only one response)____ 
 
1.  Less the 8 years     5.  Some university  
2.  8 thru 11 years     6.  University graduate 
3.  12 years or completed secondary school  7.  Postgraduate 
4.  Post secondary training other than university 
                   (vocational or technical training) 
 
 4. What is your current marital status?  (Check only one; if common-law marriage, check 1.)____ 
 
1.  Married or living as married  4.  Separated 
2.  Widowed     5.  Never married 
3.  Divorced 
 
 5.  Which of these categories best describes your current working situation?____ 
 
1.  Homemaker    5.  Extended sick leave 
2.  Working     6.  Disabled 
3.  Unemployed    7.  Other (specify) _____________________ 
4.  Retired 
 
 6.  What has been your usual adult occupation?  That is, at what type of occupation have you 
      worked the longest during your adult life? 
 
Usual adult occupation: _________________________________________________________ 
 
 7.  What were your usual activities and duties in this occupation? 
 
Usual activities or duties: _________________________________________________________ 
 
 8.  In what type of business or industry were you usually employed in this occupation? 
             
          
Business or industry: _________________________________________________________ 
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9.  How many years have you worked in this occupation? 
 
____ ____ Number of years worked in occupation 
 
10. List other jobs you have had:__________________________________________________________  
  
 
11. Have you ever worked as an agricultural worker or pesticide worker? ____ 
 
1.  No  (Go to Question 11j)  2. Yes 
 
 
11b. If yes, circle your years of age when you worked as an agricultural worker/grounds keeping more than one 
month?  (For example, if the man worked on a farm from ages 18-25, and age 45-51, draw a circle around 
the numbers 18 19 and a circle around 20 21 22 23 24 25 and a circle around 45 46 47 48 49 and a circle 
around 50 51.) 
                                                                                                             List crops or livestock tended.      
 
10   11   12   13   14   15   16   17   18   19               ______________________________________ 
 
20   21   22   23   24   25   26   27   28   29               ______________________________________ 
 
30   31   32   33   34   35   36   37   38   39               ______________________________________ 
 
40   41   42   43   44   45   46   47   48   49               ______________________________________ 
 
50   51   52   53   54   55   56   57   58   59               ______________________________________ 
 
60   61   62   63   64   65   66   67   68   69               ______________________________________ 
 
70   71   72   73   74   75   76   77   78   79               ______________________________________ 
 
80   81   82   83   84   85   86   87   88   89               ______________________________________ 
 
11c. Were chemical fertilizers used on the estate/farm/holding/plantation where you worked?___ 
 
1.  No  (Go to Question 11f)  2. Yes  3.  Don't know (go to question 11f) 
 
11d. If yes, circle all age periods when you worked on an estate/farm/holding/plantation when chemical fertilizers 
      were used. 
 
Age periods  10-19  30-39  50-59  70-79 
 
20-29  40-49  60-69  80 and older 
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11e. What chemical fertilizers were used? 
______________________________________________________________________________ 
 
______________________________________________________________________________ 
 
______________________________________________________________________________ 
 
 11f. Were pesticides used on the estate/farm/holding/plantation where you worked?___ 
 
1.  No  (Go to Question 11j)  2. Yes  3.  Don't know (Go to Question 11j) 
 
 11g. Circle all age periods when you worked on an estate/farm/holding/plantation when pesticides were used. 
Age periods  10-19  30-39  50-59  70-79 
 
20-29  40-49  60-69  80 and older   
 
 
 11h. What chemical pesticides were used when you worked on an estate/farm/holding/plantation? 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
11i. Circle your years of age when you worked as a pesticide sprayer in agriculture, grounds keeping, 
business or residential work for more than one month?   (For example, if the man worked with pesticides 
from ages 18-25, and age 45-51, draw a circle around the numbers 18 19 and a circle around 20 21 22 23 
24 25 and a circle around 45 46 47 48 49 and a circle around 50 51.) 
List pesticides used.      
 
10   11   12   13   14   15   16   17   18   19          ______________________________________ 
 
20   21   22   23   24   25   26   27   28   29          ______________________________________ 
 
30   31   32   33   34   35   36   37   38   39          ______________________________________ 
 
40   41   42   43   44   45   46   47   48   49          ______________________________________ 
 
50   51   52   53   54   55   56   57   58   59          ______________________________________ 
 
60   61   62   63   64   65   66   67   68   69          ______________________________________ 
 
70   71   72   73   74   75   76   77   78   79         ______________________________________ 
 
80   81   82   83   84   85   86   87   88   89         ______________________________________ 
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11j. Check the animals you keep?  
1.  ____  chickens  5. ____ cows             
2.  ____  ducks   6. ____ goats 
3.  ____  pigeons  7. ____ other   
4.  ____  other fowl 
  
12.  Have you ever smoked cigarettes regularly for six months or longer?____ 
 
       1.  No  (Go to Question 20)                2.  Yes 
 
13.  At what age did you start smoking cigarettes regularly? ____  
 (Enter age first started smoking in the space provided) 
 
14.  Do you smoke cigarettes regularly now?    ____ 
 
1.  No     2.  Yes  (Go to Question 16) 
 
15.  At what age did you last stop smoking cigarettes regularly?____ 
(Enter age last stopped smoking in the space provided) 
 
16.  During periods when you smoked, how many cigarettes did or do you usually smoke per 
day?____ 
1.  1-10 3.  21-30 5.  41-60 7.  81 or more 
2.  11-20 4.  31-40 6.  61-80 
 
17.  During periods when you smoked, did or do you more often smoke filter or non-filter 
cigarettes?____ 
 
1.  Filter more often  2.  Non-filter more often  3.  Both about equally 
 
18.  Do you now or did you ever smoke a pipe regularly for a year or longer? ____ 
 
1.  Never smoked a pipe    3.  Currently do smoke a pipe 
2.  Did smoke a pipe but currently do not smoke 
 
19.  Do you now or did you ever smoke cigars regularly for a year or longer?  
1.  Never smoked cigars    3.  Currently do smoke cigars 
2.  Did smoke cigars but currently do not smoke 
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20a. Do you drink alcohol? Yes___(1)  No___(2) 
 
     b. which type of alcohol do you usually take? 
          1. Beer_____ 2. Palm wine_________ 3. Ogogoro/whiskey/Liquor__________ 4. wine______ 
                                                                                     
 
 c. How often do you drink alcohol?  
           1. Daily____    2. Two to 3 times a week_____    3. Less than twice a week  4. 
Occasionally____ 
 
21. What is your position among your mother’s children (both alive and late)? 
 
 
22a. Number of whole   
sisters 
 
Number of half sisters 
 
22b. Number of whole   
brothers 
 
Number of half brothers 
 
# Living 
 
# Deceased 
 
# Living 
 
# Deceased 
 
# Living 
 
# Deceased 
 
# Living 
 
# Deceased 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22c. Number of whole sisters who live in: 
 
22d. Number of half sisters who live in: 
 
Benin-city or w/I 10 km 
 
Elsewhere in Nigeria 
 
Benin-City or w/I 10km 
 
Elsewhere in Nigeria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE FOLLOWING QUESTIONS ASK ABOUT YOUR FAMILY MEDICAL HISTORY AND YOUR PERSONAL MEDICAL HISTORY. 
 
 
 
 
22c.  Is your mother living?____ 
1.   No, deceased     3. Yes living elsewhere in Nigeria 
2.   Yes living in/near Benin-City.   4. Yes, living outside Nigeria 
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23a.  Have parents, children, brothers, sisters, half-brother, or half-sisters ever been diagnosed 
 as having any type of cancer?  (Do not include Basal-Cell Skin Cancer) 
 
1.  No  (Go to question 23c)  2.  Yes 
                                                                                                                    
 
23b. Please complete this chart for each relative (mother, father, children, brothers, sisters, 
half-brother, or half-sisters) diagnosed with cancer?  (Do not include Basal-Cell Skin Cancer)  (If 
you have more than four relatives diagnosed with cancer, please include a separate page with 
this information.) 
 
    
Male/Female   Type of cancer Age at diagnosis 
1st Relative ______________________________________________________________________     
 
2nd Relative ______________________________________________________________________ 
 
3rd Relative _______________________________________________________________________ 
 
4th Relative _______________________________________________________________________ 
 
23c. Have any of your relatives been diagnosed with fibrocystic disease of the breast? Yes___ 
No___ 
 
24.  What is or was your weight at these ages?  (Enter the weight in pounds in the space 
provided) 
 
Weight at Age 50? ___ ___ ___  Weight at Age 20?___  ___ ___  Current Weight?___ ___ ___ 
 
25.  How tall are you?  (Record your height in feet and inches in the space provided.) 
 
Feet _____ Inches _____ _____  
 
 
26.  During the last 12 months, have you regularly used aspirin or aspirin-containing products, such 
Bufferin, Anacin, cafenol, disprin, phensic, alka seltzer?  (Please do not include aspirin-free products 
such as Tylenol and Panadol.) ____1.  No (Go to Question 28)  2.  Yes 
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27.  During the last 12 months, how many pills of aspirin or aspirin-containing products did 
you usually take per day, per week, or per month? ____ 
1.  1 per day    4.  2 per week  7.  2-3 per month 
2.  2 or more per day  5.  3-4 per week 
3.  1 per week   6.  Less than 2 per month                                                                                     
 
28.  During the last 12 months, have you regularly used ibuprofen-containing products, such 
as Advil, Nuprin, Motrin, olfen, feldene, indocin? ____ 
 
1.  No (Go to Question 30)  2.  Yes 
 
29.  During the last 12 months, how many pills of ibuprofen-containing products did you 
usually take per day, per week, or per month? 
 ____ 
1.  1 per day   4.  2 per week   7.  2-3 per month 
2.  2 or more per day  5.  3-4 per week 
3.  1 per week   6.  Less than 2 per month 
 
30.  Has the doctor ever told you that you have any of the following conditions?   
(Mark Yes, No or Don’t Know for each condition) 
 
  1   2    3 
No   Yes Don’t Know 
___ ___    _____ High blood pressure (hypertension) 
___ ___    _____ Coronary heart disease/heart attack 
___ ___    _____ Stroke 
___ ___    _____ Emphysema 
___ ___    _____ Chronic bronchitis 
___ ___    _____ Diabetes 
___ ___    _____ Colorectal polyp(s) 
___ ___    _____ Arthritis 
___ ___    _____ Osteoporosis 
___ ___    _____ Hepatitis 
___ ___    _____ Cirrhosis 
___ ___    _____ Diverticulitis/diverticulosis 
___ ___    _____ Gall bladder stones or inflammation 
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31. Have you ever been diagnosed as having breast cancer?   
 
1.  No (Go to Question 33)  2.  Yes, age at diagnosis __________ 
                                                                       
 
32. Have you ever been diagnosed with any type of cancer other than breast cancer? (Do not 
include Basal-Cell Skin Cancer).  
 
What type of cancer did you have? How old were you when you were 
diagnosed with this cancer? 
1st 
Cancer 
_____________________ 
Type of cancer 
____________ 
Age 
2nd 
Cancer 
_____________________ 
Type of cancer 
____________ 
Age 
3rd 
Cancer 
____________________ 
Type of cancer 
____________ 
Age 
 
33. At what age did you first began your menstrual period?    ______________ 
 
34a.  Are your menstrual periods regular?    1. No______________      2. Yes_______________ 
 
34b. Date of Last Menstrual Period    --------------------------------------- 
 
35a. Have you ever (or are you currently) taking female hormones for birth control? 
 
    1. No________      2. Yes__________   3. Don’t know________________ 
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b. Dates or time period, name of pill  
 
Name of birth control pill Age at onset of use Duration of use (months) 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
36a. Have you ever taken female hormones other than for birth control? 1. No_____  2. Yes____  
3. Don’t know___ 
 
    b. Dates or time period, name and 
reason:______________________________________________________        
____________________________________________________________________________________________ 
 
37.a.  At what age did you experience menopause (absence of menstrual period for more than 1 
year)? 
       ___________ Years 
 
     b. Did you receive any medications because of menopause?   
         1. No________    2. Yes_____________    3. Don’t know_____________ 
 
If the subject indicates that medication was received because of menopause, complete questions 37c and 37d. If the 
subject did not receive any medication because of menopause, continue with question 38a. 
 
     c. What type of medicine? 
                    (List names of medications below when possible) 
                     Tranquilizer?              1. No________  2. Yes__________   3. Don’t 
know_____________  
                     Pain Killer                   1. No________  2. Yes__________   3. Don’t 
know_____________ 
                     Female Hormones   1. No________  2.  Yes__________   3. Don’t know_____________ 
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     d. How many months have you taken female hormones 
 
Name of Hormone (HRT) Age at onset of use Duration of use (months) 
 
   
 
   
 
 
     e. Are you currently taking the female hormones?   1. No_________   2. Yes_________ 
 
38a. Have you had any of the following operations? 
 
        Caesarean section (operation for delivery) 1. No_____   2. Yes________  3. Don’t 
know_______ 
        
        Tubal ligation (tubes tied for family planning) 1. No_____   2. Yes________  3. Don’t 
know_______ 
 
        Hysterectomy (womb removed at operation) 1. No_____   2.Yes________   3. Don’t 
know_______ 
 
If the subject indicates that she had hysterectomy, complete questions 38b. If the subject did not have hysterectomy, 
continue with question 38c. 
 
   b. Did they remove the ovaries with the womb? 1. No_____   2. Yes_______    3. Don’t 
know_______ 
 
   c. What type of medicine were you given after the operation? (List the names of the 
medications when possible). 
       Pain Killer?                      1. No_______      2. Yes__________     3. Don’t know_______________ 
 
      Antibiotics?                      1. No_______      2. Yes__________     3. Don’t know_______________  
        
       Female Hormones?         1. No_______      2. Yes__________     3. Don’t know_______________ 
      
   d. How many months have you taken female hormones?   __________months 
 
   e. Are you currently taking female hormones?  1. No________      2. Yes__________ 
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39a. How many children do you have?  ________________ 
 
39b. History of childbirths/pregnancies and breastfeeding (Include all abortions, indicate 
whether spontaneous or induced). 
 
Child/preg
nancy No. 
Date of birth Duration of pregnancy Duration of breastfeeding 
(months) 
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40. At what age did you have your first live birth                               _____________                                             
41. At what age did you have your first pregnancy over 6 months (alive or late)? ____________ 
 
42a. Did you breastfeed?   1. No_____________    2. Yes________________ 
 
    b. How many months did you breastfeed your children? ______________ 
 
43. Have you had any of the following surgical procedures of the breast? 
 
       1. Biopsy                                              4. Breast surgery, type unknown 
       2. Surgery for benign disease               5. None (Go to Question 45)    
       3. Mastectomy for breast cancer           6. Don’t know (Go to Question 45)  
 
44. How old were you when you had a surgical procedure for breast cancer for the first time?  
 
          1. Less than 30              3. 40-49                         5. 60-69 
          2. 30-39                        4. 50-59                        6. 70-older                
 
 
45a. During the past year, have you had a breast examination? 
                   
           1. No_______     2. Yes, once _________   3. Yes, more than once_____   4. Don’t 
know______   
 
    b. During the past month, have you done a Self-breast examination? 
 
           1.No________     2. Yes, once________      3. Yes, more than once_____   4. Don’t 
know______ 
 
 
46. How would you rate your awareness of breast disease? (e.g. painful/painless breast lump, 
bloody              nipple discharge or ulceration)?  
 
          1. Very high_______   2. High_________      3. Low___________       4. Very low 
 
 
47.  What is the date you completed this questionnaire?        _____/_____/_____  
                                                                                            Day    Month   Year       
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Following Measurements with light clothing, without shoes 
 
48.  Height  ________cm  ____ ___ ___. ___ 
 
49.  Weight ________kg ____ ___ ___. ___ 
 
50.  Waist _________cm (at umbilicus) ___ ___. ___ 
 
51.  Hips __________cm (at widest part of buttocks) ___ ___. __ 
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 APPENDIX B: CONSENT FORM 
 
University of Pittsburgh       IRB # 010767 
Graduate School of Public Health         
        NB0 2 __ __ __ __ __ __ __  
          
CONSENT TO ACT AS A SUBJECT IN A CLINICAL STUDY 
 
Title: Estrogens, Genetic Polymorphisms and Breast Cancer Risk 
 
INVESTIGATORS:  University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA 
   Clareann H. Bunker, Ph. D., Assistant Professor, Department of  
   Epidemiology (412) 624-3467. 
 
Robert E. Ferrell, Ph.D., Professor, Department of Human Genetics. (412) 
624-3018 
 
Lewis H. Kuller, M.D., Dr.PH, Professor and Chairperson, Department of 
Epidemiology (412) 624-3054 
 
Department of Surgery, Uviversity of Benin/University of Benin Teaching 
Hospital, Benin-City, Nigeria  
Michael N. Okobia, MBBS, Senior Lecturer, Tel: 234 52 600621.  
Department of Surgery, Nnamdi Azikiwe University/Nnamdi Azikiwe 
University Teaching Hospital, Nnewi, Nigeria 
Stanley N.C. Anyanwu, M.B.B.S., FMCS, FWACS, Associate Professor, 
Tel: 234 46 251912  
Department of Surgery, University of Nigeria/University of Nigeria 
Teaching Hospital, Enugu, Nigeria. 
Ezeome E.R., M.B.B.S., FWACS, Lecturer/Consultant Surgeon. 
Department of Surgery, University of Port Harcourt/University of Port 
Harcourt Teaching Hospital, Port Harcourt, Nigeria 
Uche E.E.O., M.B.B.S., SCGS, Ph.D, FWACS, Lecturer/Consultant 
Surgeon. 
 
SOURCE OF SUPPORT: U.S. Department of Defense (Pending) 
 
DESCRIPTION:  You are being asked to participate in a genetic research study involving breast 
cancer.   We want to study the genetic factors in the body, called genes or DNA, which may help 
cause breast cancer in some women.  We plan to compare these genes in women who have breast  
Cancer with these genes in women who do not have breast cancer. You are being asked to be in 
the study because you have breast cancer or because you are a hospital patient without breast 
cancer. The study will require one visit. At the visit, a breast examination will be conducted. If 
you do not have cancer and the doctor finds that your breast has a lump, you will not be eligible  
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to continue in the study. If you are eligible to continue, we will record your height, weight, and 
other physical measurements. We will also ask questions from the Breast Cancer Questionnaire 
about your history of cancer, and medical, work, and smoking history.  This will take about 30 
minutes. 
 
Blood and urine samples will be collected from you to test for factors, e.g. female hormones, 
related to breast cancer.  Female hormones are substances in the body which are related to the 
female organs, e.g. the breasts, ovaries and uterus.  The DNA tests will be done on the blood 
sample.  A vial with a needle at the top will be stuck into a vein in your arm to draw a small 
blood sample (about four teaspoons).  Part of your blood and urine samples will be stored 
indefinitely at the University of Pittsburgh for possible future research tests to help understand 
the causes of breast cancer.  
 
If you have breast cancer, we also request your permission for us to review your medical record 
and obtain a copy of the report of the doctor’s examination of your breast tissue  
under the microscope at the pathology department of University of Benin Teaching 
Hospital/Nnamdi Azikiwe University Teaching Hospital/University of Nigeria Teaching 
Hospital/University of Port Harcourt Teaching Hospital. This review of your medical record will 
be completed within the next year.  
 
If you agree to participate in the research project, use of your biological and genetic material will 
be under the control of the principal investigator of this research project. 
 
RISKS AND BENEFITS: There are no benefits for participation in this study. Your blood will 
be taken from your arm by one of the local doctors working on the study. There may be a little 
discomfort or a bruise on your arm. You may feel dizzy or faint, but this would be rare.  The 
breast examination will be performed by a specialist surgeon. 
 
The DNA tests and other future research tests are not ordinary medical tests which doctors use to 
help decide your care.  Instead, these are special tests that are being done for research and the 
results have no known benefit to you.  Therefore, you will not receive these results.  However, as 
a result of these tests, we expect to learn about factors that may cause breast cancer.  This 
knowledge may be of benefit to others in the future. To minimize the risk of social stigma 
associated with DNA tests, the results of these tests will be kept strictly at the University of 
Pittsburgh. The result of these tests will not be made available to your doctor. The results of the 
DNA test will not bear your name, they will be identified by code numbers and will only be used 
for research purposes 
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COSTS AND PAYMENTS: Your biological sample or genetic material may lead, in the future, 
to new inventions or products. If the research investigators are able to develop new products 
from the use of your biological sample or genetic material, there are currently no plans to share 
with you any money or other rewards that may result from the development of the new product. 
        
SAMPLE PROVISION: 
Our knowledge of the causes of breast cancer are limited and new factors may be studied over 
time.  We will save your samples for up to 20 years in order to try to identify genes, or factors in 
the blood, or factors in the urine, which will help us to understand why some women get breast 
cancer while others do not.  We don't know exactly what will be important to test, but factors 
which may be studied include hormone levels in the blood and urine, infectious agents, and 
genes which may influence the effects of hormones, vitamin D, and dietary factors.  The results 
of these further tests will be for research and will not be provided to you.  We will use these 
samples for other types of studies, i.e., studies not involving breast cancer, only after asking 
again for your consent. 
 
Do you accept to have your blood and urine samples stored for up to 20 years for future study?   
Yes              No  
 
Your refusal to sign the sample consent form does not make you ineligible to participate in this 
study. 
 
Your biological samples will be stored without identifiers in University of Pittsburgh for up to 20 
years or until used in approved investigations. Storage arrangements may change in response to 
emergency conditions or approved change in protocol. Your biological samples will be under the 
control of the principal investigator of this project. Your biological samples may be provided to 
secondary investigators without identifiers. 
 
You may request that your biological samples be destroyed at any time and such request are to 
be made in writing to the principal investigator, or any of the co-investigators in Nigeria who 
will then pass the request to the coordinating center at Department of Epidemiology, University 
of Pittsburgh. Upon receipt of such a request, your samples will be pulled out from the storage 
using your identifier number. These samples will then be destroyed according to University of 
Pittsburgh protocol for disposal of biological samples.    
 
CONFIDENTIALITY: Any information obtained about you in this research, including history, 
and laboratory data will be kept confidential. All records obtained from you in the course of this 
research including questionnaires and medical chart collection sheets will be transferred from the 
various study sites in Nigeria personally by the principal investigator and stored in a locked file 
cabinet in Nigeria. The records will be carried personally by the principal investigator as a hand 
luggage from Nigeria to the University of Pittsburgh. All records pertaining to you will be stored 
in a locked file cabinet at the University of Pittsburgh, and will only be accessible to the 
investigators listed on the first page of this informed consent form. We will give health 
information, for example the results of your breast examination, to your doctor or hospital at  
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your written request. You do understand that research records, like hospital records may be 
subpoenaed by court order in the United States, but this is unlikely to occur and would not affect 
you in any way. Your blood and urine samples will not have your name on it, but it will be 
identified with a code number to insure confidentiality during analysis and storage at the 
University of Pittsburgh. The result of the DNA testing (genotyping) will not be placed in your 
medical record or given to your doctor, it will be used only for research purposes. All the 
information that will be obtained from you will be stored in the computer database using 
identification numbers without your name. The questionnaires, medical chart collection sheets, 
data and other paper documents used in this study will be stored for five  years after which they 
will be destroyed according to the University of Pittsburgh protocol for the disposal of research 
documents. 
 The U.S. Army Medical Research and Materiel Command are eligible to review research 
records as part of their responsibility to protect human subjects in research. 
You consent to the publication of study results so long as the information is anonymous and/or 
disguised so that no one could identify you. The University Research and Conduct Office may 
review these research records. 
        
RIGHT TO WITHDRAW: You understand that you are free to refuse to participate in this study 
or to withdraw at any time. Your decision will not adversely affect your care at the University of 
Pittsburgh, the University of Benin Teaching Hospital/Nnamdi Azikiwe University Teaching 
Hospital/University of Nigeria Teaching Hospital/University of Port Harcourt Teaching Hospital 
or your employment, nor will it cause a loss of benefits, which you might otherwise receive.  
You retain the right to have your blood samples and its DNA destroyed should you decide to 
withdraw from the research study.  
 
COMPENSATION FOR ILLNESS OR INJURY: Should you be injured as a direct result of 
participating in this research project, you will be provided with medical care at no cost to you for 
that injury. You will not receive any injury compensation, only medical care. You should also 
understand that this is not a waiver of release of your legal rights. You should discuss this issue 
thoroughly with the principal investigator before you enroll in this study. 
 
VOLUNTARY CONSENT: I certify that I have read the preceding, or that it has been read to 
me. Dr. Michael Okobia , who may be contacted at the University of Benin Teaching Hospital, 
234 52 600621; or Dr. Stanley N.C. Anyanwu, Nnamdi Azikiwe University Teaching Hospital, 
234 46 251912; or Dr. Emmanuel R. Ezeome, University of Nigeria Teaching Hospital, 234 42 
254623; or Dr. Emmanuel E.O. Uche, University of Port Harcourt Teaching Hospital, 234 84 
238923; or Dr. Clareann Bunker, University of Pittsburgh (412-624-3467) will answer any 
questions I have about this study.   Any questions I have about my rights as a research subject 
will be answered by the Human Subject Protection Advocate, Institutional Review Board (IRB) 
Office, University of Pittsburgh (412-578-8570).   
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By signing this form, I agree to participate in this research study. 
 
I,_____________________________________, consent to participate in this study.  
 
               (Please Print Name) 
             
I understand the nature, purpose, potential risks and benefits associated with  
Participation, and all of my questions I have been answered. 
 
Date ____________________               Signature _____________________ 
 
Date ____________________                Witnessed by __________________ 
 
Permanent Address of Participant: ____________________________________________ 
 
________________________________________________________________________ 
 
 
INVESTIGATOR CERTIFICATION 
 
I certify that I have explained to the above individual the nature and purpose, the potential 
benefits, and possible risks associated with participating in this research study,  
have answered any questions that have been raised, and have witnessed the above signature. 
 
Date _______________________           ____________________________________ 
                                                                                    Investigator’s signature 
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 APPENDIX C: MAP OF NIGERIA SHOWING STUDY SITES 
   
Figure 10-1: Map of Nigeria showing the Breast Cancer Study Sites 
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